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Michael A. Cowley 4, Carrie Haskell-Luevano 3, Lex Van Der Ploeg 7, Roger A.H. Adan 8,9ABSTRACT
Background: Over the past 20 years, insights from human and mouse genetics have illuminated the central role of the brain leptin-melanocortin
pathway in controlling mammalian food intake, with genetic disruption resulting in extreme obesity, and more subtle polymorphic variations
influencing the population distribution of body weight. At the end of 2020, the U.S. Food and Drug Administration (FDA) approved setmelanotide, a
melanocortin 4 receptor agonist, for use in individuals with severe obesity due to either pro-opiomelanocortin (POMC), proprotein convertase
subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
Scope of review: Herein, we chart the melanocortin pathway’s history, explore its pharmacology, genetics, and physiology, and describe how a
neuropeptidergic circuit became an important druggable obesity target.
Major conclusions: Unravelling the genetics of the subset of severe obesity has revealed the importance of the melanocortin pathway in
appetitive control; coupling this with studying the molecular pharmacology of compounds that bind melanocortin receptors has brought a new
obesity drug to the market. This process provides a drug discovery template for complex disorders, which for setmelanotide took 25 years to
transform from a single gene into an approved drug.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Obesity is associated with comorbidities such as type 2 diabetes,
cardiovascular disease, and certain cancers and is arguably the
greatest public health threat of the twenty-first century. While its
increasing prevalence worldwide has clearly been driven by our
changing lifestyle, a powerful genetic component underlies the large
variations in body weight within this modern environment. Twin and
adoption studies have revealed the heritability of the body mass index
(BMI; weight in kg/height in m2) to be between 40% and 70% [1,2].
Over the past two decades, studies of human and mouse genetics have
uncovered a number of circuits within the brain that play a central role
in modulating mammalian appetitive behaviour and metabolism. The
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www.molecularmetabolism.compathway, genetic disruption of which causes the majority of monogenic
severe obesity disorders in both mice and humans.
The melanocortin system refers to a set of hormonal and neuro-
peptidergic pathways that are comprised of three main components:
pro-peptide proopiomelanocortin (POMC), which is post-translationally
processed by prohormone convertases into a number of biologically
active moieties, including a-melanocyte stimulating hormone (MSH),
b-MSH, g-MSH, and adrenocorticotrophin (ACTH) [3], the eponymous
melanocortin peptides; the five G protein-coupled melanocortin re-
ceptors, MC1R-MC5R, that mediate their actions [4]; and endogenous
antagonists of those receptors, agouti and agouti-related protein
(AgRP). The system is responsible for a dizzying array of functions,
from melanogenesis and adrenal development, to energy homeostasis
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Reviewregulating food intake and body weight in particular. At the end of
2020, the U.S. the Food and Drug Administration (FDA) approved the
MC4R agonist setmelanotide for chronic weight management in adult
and paediatric obesity patients due to POMC, proprotein convertase
subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency [5].
We chart the pathway’s history, explore its pharmacology, genetics,
and physiology, and describe how a neuropeptidergic circuit became
an important druggable obesity target.
2. HISTORY AND CLONING OF MELANOCORTIN RECEPTORS
The effects of ACTH and MSH on the adrenal gland and pigmentation,
respectively, were well known before direct effects of melanocortin
peptides on the brain were described in the 1950s [6]. In the late
1970s, the discovery of melanocortin peptide immunoreactivity in the
rat brain, coupled with cloning the POMC gene and the subsequent
demonstration that it was expressed in the hypothalamus in the early
1980s indicated the existence of a brain melanocortin system [7]. The
arcuate nucleus of the hypothalamus (ARC) and the nucleus of the
tractus solitarius (NTS) are the main sites of POMC expression in the
brain. However, it took until the late 1980s before binding sites for
melanocortins could be demonstrated in the brain [8]. By that time,
various effects were described of MSH and ACTH fragments on rodent
behaviours [9], but the prominent effects of melanocortins on feeding
and body weight regulation remained unknown. There were only a
handful of studies describing the effect on feeding [10].
In 1992, receptors for the two “original” melanocortin peptides, a-
MSH and ACTH, were cloned [11]. MSH was so named because of the
peptide’s ability to stimulate the synthesis of melanin by melanocytes,
and its receptor, initially called MSH-R, was cloned from a melanoma
sample known to be able to bind high levels of MSH. Given that a-MSH
represents the first 13 amino acids of ACTH, literally being a part of the
longer 39 amino acid peptide, it is unsurprising that their receptors
share a great deal of sequence homology, which was how the ACTH-R
was cloned. Similar methods leveraging sequence homology were
then used to clone three additional melanocortin receptors, two of
which were expressed primarily in the brain and the other in peripheral
tissues. Their eventual names reflected the order in which they were
cloned, with MSH-R and ACTH-R being renamed MC1R and MC2R,
respectively; the two brain receptors followed as MC3R [12,13] and
MC4R [12] and finally the peripheral MC5R was cloned [14].
3. THE LINK BETWEEN THE MELANOCORTIN PATHWAY AND
ENERGY BALANCE
POMC is expressed in hair follicles, the skin, pituitary cells, and
neurons in the hypothalamus and brain stem [3]. The precursor peptide
of POMC is cleaved by peptidases including PCSK1, proprotein con-
vertase subtilisin/kexin type 2 (PCSK2), carboxypeptidase E (CPE),
peptidyl-a-amidating monooxygenase (PAM), N-acetyltransferase (N-
AT), and prolyl carboxypeptidase into different products in different cell
populations, yielding, for example, ACTH in the pituitary corticotrophs
vs a- and b-MSH in neurons localised to the arcuate nucleus (ARC) of
the hypothalamus. Within the pituitary, POMC is expressed in excitable
cells that produce ACTH and cells in the intermediate lobe that express
a-MSH [3]. While agonists stimulate the production of cyclic adenosine
monophosphate (cAMP) and recruitment of b-arrestin, they regulate a
variety of physiological effects [4]. These include skin and hair
pigmentation (MC1R), steroidogenesis (MC2R), appetite, satiety, en-
ergy homeostasis (MC3R/MC4R), and exocrine gland function (MC5R)
in mice.2 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. TThe linking of the melanocortin system to the regulation of body weight
came with the study of a bright yellow mouse with severe obesity.
Because the coat colour of animals is easily observed, pigmentation
genetics became popular, including the hunt for genetic loci affecting
coat colour. One of the classical genetic loci that influenced coat colour
and pigmentation in several mammalian species was the extension
locus, which encoded MC1R [15]. Yet another was the agouti locus,
shown to be upstream of extension or MC1R. Agouti is normally
expressed in the skin and acts as an antagonist on MC1R [16],
blocking the production of darker melanin and producing lighter
phaeomelanin, which in mice is a yellow-orange colour. Agouti mice
have a mutation within the promotor that results in constitutive and
ectopic production of the agouti peptide [17,18]. However, in addition
to altered pigmentation, because agouti, which is normally expressed
only in the skin, when ectopically expressed in the brain also antag-
onises MC4R [16,19], the mice are also hyperphagic and severely
obese. The demonstration that Agouti also acts as an antagonist for the
MC4R was a hallmark finding that launched the awareness that the
melanocortin system plays a role in body weight regulation [16]. Based
on its homology to agouti, agouti-related protein (AgRP) was cloned
and shown to be expressed in the hypothalamus as natural antagonists
of MC3R and MC4R [20], but not MC1R. Thus, transgenically over-
expressing AgRP in mice resulted in hyperphagia and obesity, but not
the characteristic coat colouration seen in agouti mice. We now know
that a key physiological role of MC4R neurons within the para-
ventricular nucleus of the hypothalamus (PVN) is sensing the balance
of orexigenic AgRP and anorexigenic melanocortin signals and to
regulate feeding behaviour and energy expenditure [21] (Figure 1).
4. POMC NEURONS: KEY REGULATORS OF ENERGY
EXPENDITURE AND SATIETY
Within the ARC, POMC neurons are found adjacent to the medium
eminence/tubero-infundibular zone at the base of the third ventricle,
just above the pituitary stalk. Most of these neurons co-express
cocaine- and amphetamine-related transcript (CART) peptide and
project widely throughout the brain [22]. In the brainstem, NTS POMC
neurons are thought to respond to, among other signals, gut-secreted
cholecystokinin (CCK) [23] and adipocyte-derived leptin [24].
Over the past 20 years, the role of ARC POMC neurons in energy
homeostasis, particularly in response to the adipocyte-derived hor-
mone leptin, has been extensively studied [22]. Various peptide
products of the POMC precursor have different receptors, so one needs
to be cautious about fully ascribing POMC neuron actions with a
discrete peptide receptor. Nevertheless, melanocortin peptides acting
through central MC4R have a clear role in regulating appetite, energy
expenditure, and body weight [22]. Because much of the initial char-
acterisation of POMC peptides was performed in rodents that crucially
lack cleavage sites to produce b-MSH, a-MSH was thought to be the
key effector with respect to energy homeostasis. However, genetic
evidence from humans [25] and dogs [26] point to b-MSH having at
least as important a role as a-MSH, particularly in signalling through
MC4R. Additionally, melanocortin peptides have been shown to
regulate glucose homeostasis [27], erectile function [28], and car-
diovascular tone [29], and peripherally to regulate skin and coat col-
ouration, inflammation, skeletal muscle glucose uptake, and gut
function [4].
POMC neurons are central mediators of endocrine signals. A significant
proportion of ARC POMC neurons are activated by leptin expressing
both STAT-3 and the immediate early gene c-fos. They are also
activated by increasing blood glucose [30] by GLP-1R agonists [31]his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Schematic illustrating POMC (red) and AgRP (blue) neuronal projections from the arcuate nucleus of the hypothalamus (ARH) to the lateral hypothalamus (LH), par-
aventricular nucleus of the hypothalamus (PVH), central nucleus of the amygdala (CEA), bed nucleus of the stria terminalis (BST), lateral parabrachial nucleus (LPB), reticular
formation (RET), dorsal motor nucleus of the vagus (DMV), area postrema (AP), and nucleus of the solitary tract (NTS). POMC and AgRP neurons arise in the ARH adjacent to the
median eminence (ME) and project widely. POMC neurons in the NTS have a more restricted set of projections. Both sets of neurons appear able to receive neural and endocrine
signals from the body.and inhibited by ghrelin [32]. It remains unclear if POMC neurons are
activated by PYY3-36 [33,34]. POMC neurons are implicated in several
models of cachexia [35,36]. It is unclear what the effect of insulin is on
these neurons [37,38,39]. In general, POMC neurons are more active
in post-nutritional repletion states than in fasting states [40].
Endocrine factors that activate POMC neurons cause anorexia and
weight loss. These effects are mimicked by local application of a-MSH
and are diminished in mice that lack MC4R [41], while food intake is
supressed in mice lacking MC3R [42]. This shows that a-MSH sig-
nalling through the MC4R axis is at least partly responsible for some of
these endocrine effects. In general, anorectic actions of melanocortin
signalling at MC4R are considered to occur through neurons in the PVN
[43,44,45], but neurons in other areas as the amygdala, DMH, and
MPO [46] also contribute to the effects of melanocortins on appetite
[44,45,47,48,49]. MC4R expressed on sympathetic preganglionic
cholinergic neurons mediate actions on energy expenditure and
glucose homeostasis by increasing sympathetic nervous system ac-
tivity [50]. Sympathetic activation also mediates the effects of some
melanocortins on heart rate and blood pressure, although the site of
these receptors or their precise identity (MC3R vs MC4R) has not been
determined [28]. Lateral hypothalamic MC3R-expressing neurons also
modulate locomotor and energy expenditure activity [51].
Our understanding of the central melanocortin system has increased
but the precise neural mechanisms by which it regulates appetite and
energy expenditure are incompletely understood. The POMC system
remains an intriguing drug target because of its importance in main-
taining energy homeostasis and its capacity to influence several
physiological processes.
5. AGRP NEURONS: AN INTEGRATED CONTROLLER OF
FEEDING AND BEYOND
Soon after the discovery of AgRP, it was clear that while its over-
expression resulted in hyperphagia and obesity, deleting the gene in
mice did not result in a reduced body weight phenotype. It was not until
four groups independently ablated the neurons expressing AgRP in
adult mice, leading to an acute reduction in food intake to the point of
starvation, that the necessity of those neurons to sustain feedingMOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
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genetic and optogenetic stimulation of AgRP neurons increased food
intake, demonstrating that AgRP neurons are also sufficient to engage
feeding behaviour [55,56]. The fast-acting neurotransmitter GABA,
which is co-released by AgRP neurons [57], was identified as a critical
component of the rapid effects following AgRP neuron stimulation on
food intake. Intriguingly, starvation induced by AgRP neuron ablation
could not be rescued by chronic antagonism of MC3R and MC4R,
whereas delivery of the GABA mimetic bretazenil to the parabrachial
nucleus (PBN), where AgRP neurons densely project, could restore
feeding and preserve body weight [55,58,59]. These results suggest
that some behavioural and metabolic responses initiated by AgRP
neuron activation might be independent of AgRP’s role as an antag-
onist at melanocortin receptors. It was later shown that chemogenetic
and optogenetic stimulation of AgRP neuron cell bodies or specific
post-synaptic projections triggered a rapid feeding response that relies
on GABA and NPY release, while AgRP release promoted a delayed and
prolonged feeding response [60,61]. These results indicate that the
kinetics of neuropeptide and other neurotransmitter release are
paramount to both acute behavioural responses triggered by AgRP
neurons and the neuromodulatory effect they promote at post-synaptic
targets.
Since the original studies mapping the diversity of AgRP neuron pro-
jections to hypothalamic and extrahypothalamic regions [62], tracing
methods combined with direct stimulation subsets of AgRP axons at
post-synaptic targets have allowed the unravelling of redundant and
parallel neural circuits through which AgRP neurons control food
intake, metabolism, and cognitive-related responses. These ap-
proaches made possible the ability to functionally distinguish the cir-
cuits through which AgRP neuronal activity promotes or maintains food
intake. As we previously discussed, acute loss of GABAergic input from
AgRP neurons to the PBN appears to be the primary mechanism by
which AgRP neuron ablation leads to starvation [58,59].
While direct stimulation of ARC AgRP neuronal / PBN projections
failed to increase feeding [63], genetic or pharmacological inhibition of
the PBN prevents the starvation that results from ablation of all AgRP
neurons [58]. In the PBN, calcitonin gene-related peptide (CGRP)-
expressing neurons, a critical integrative population of viscero-ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Reviewsensitive excitatory inputs from cholecystokinin (CCK)-expressing
neurons in the NTS and catecholaminergic dopamine b-hydroxylase
(Dbh)-expressing neurons in the raphe nucleus [64], were identified as
a primary relay for ARC AgRP neuronal / PBN connections. Addi-
tionally, activation of PBN CGRP neurons projecting to the central
nucleus of the amygdala (CeA) suppresses feeding [65], with activation
of PBN-induced meal termination [66] sufficient to mimic conditioned
taste aversions caused by malaise or nausea [67]. Moreover, it was
shown that inhibition of CGRP neurons through direct stimulation of
fibres projecting from AgRP neurons onto PBN CGRP neurons (ARCAgRP
/ PBNCGRP) resulted in increased feeding, even with exposure to
anorectic signals LiCl, amylin, or CCK, but not when exposed to the
inflammatory-related lipopolysaccharide signal (LPS). This study
underscored a role of the ARCAgRP / PBNCGRP network in gating
feeding response during homeostatic needs [68].
Conversely, for the PBN, direct stimulation of ARC AgRP projections to
the periaqueductal grey area (PAG) or CeA failed to promote feeding,
while [60] a positive response was observed after stimulation of AgRP
neuron projections to the paraventricular thalamus (ARC AgRP / PVT),
the anterior division of the bed nucleus of the stria terminalis (ARCAgRP
/ aBNST), the lateral hypothalamus (ARCAgRP / LH) [60] or the PVN
(ARCAgRP / PVN). In fact, functional circuit mapping has identified a
critical role of ARC AgRP neuron synapsing onto PVN oxytocin-
producing neurons (ARCAgRP / PVNOXT) for a rapid feeding
response evoked by both GABA and NPY release [61,63], while inhi-
bition of PVN MC4R-bearing neurons also demonstrated to be instru-
mental for AgRP neuron-mediated feeding through PVNMC4R / LPBN
circuits [44]. Deletion and re-expression of MC4R restricted to the PVN
allowed the glutamatergic nature of PVNMC4R neurons [45] and
prodynorphin-expressing PVN neurons (PVNPDYN) as two independent
and additive circuits mediating anorexia through direct projection onto
the PBN to be uncovered [45]. ARC / PVN projections from gluta-
matergic neurons expressing the OXY receptor, but independent from
AGRP or POMC neurons, were discovered to promote a rapid anorectic
response on a scale comparable to the rapid orexigenic response
achieved through AgRP neuron chemo/optogenetic activation [48].
To further add to the overall complexity of hunger-activated circuits,
transcriptomic studies and functional tracing revealed the diversity
among AgRP neurons based on projection sites and specific receptor
equipment for circulating metabolic signals [60,63,69]. Hence, an
ARCAgRP / PBNCGRP / CeA circuit appears to be critical to prevent
various aspects of food avoidance or aversion, ARCAgRP/ aBNST, PVN,
LH, and PVT seem rather engaged in the positive regulation of feeding.
Aside from their ability to integrate circulating signals of hunger and
satiety, in vivo recording of calcium-based fluorescence in AgRP
neurons, used as proxy of neuronal activity, revealed that AgRP neu-
rons can also rapidly process food-related cues and interoceptive
signals. The increase in AgRP neuronal activity induced by food
deprivation is rapidly dampened by the sensory detection of food, even
before calories are ingested [70,71,72], while stimulation of intestinal
mechanosensory information routed by the vagal nerve can durably
inhibit AgRP neuron activity [73,74,75,76]. Hence, AgRP neurons
critically influence a broad array of behavioural and physiological re-
sponses that, beyond the strict consummatory sequence, ensures the
optimisation of strategies (prediction, caloric evaluation, sensory, and
interoceptive signals) for foraging food and conserving body weight.
This includes the role of AgRP neurons in non-consummatory
behaviour involved in decision-making when balancing the need for4 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. Tfood and the risk associated with food retrieval. Thus, the AgRP
neuronal network functions as a core hub integrating the constellation
of responses required for the adaptive response to food availability.
6. GENETICS OF THE MELANOCORTIN SYSTEM
The discovery that mutation of the leptin gene explained the phenotype
of the obese/obese mouse in 1994 [77] heralded the modern era of
genetic and mechanistic obesity studies, making clear that regulating
food intake, and hence body weight, went beyond simply “will-power.”
In 1997 came the report of two young cousins with severe early onset
obesity harbouring leptin mutations [78], and in 1998, that of three
sisters with similar obesity with mutations in their leptin receptors [79],
confirming that this system was relevant across mammalian species.
We now know that the role of leptin, which is secreted by adipocytes
into the circulation in proportion to fat mass [80], is to inform the brain
of long-term energy stores and turn on the starvation response when
levels drop beyond a certain threshold, pointing to a role of leptin in
controlling the neuroendocrine system during starvation [81]. Crucially,
the melanocortin pathway is one of the key effector mechanisms of
leptin signalling in the brain, certainly in terms of appetite regulation.
The first direct genetic evidence of the melanocortin pathway in energy
homeostasis came in 1997 from the targeted disruption of MC4R in
mice [82], which resulted in hyperphagia, severe obesity and hyper-
insulinaemia. Over the next few years, torrents of genetic findings were
reported, in both humans and mice, that delineated most of the central
melanocortin pathway’s key components. As previously mentioned,
generating melanocortin peptides from POMC depends on a series of
enzymes. The first step is affected by proconvertase 1 (PC1), followed
by proconvertase 2 (PC2) and carboxypeptidase E (CPE). The same
year, loss-of-function mutations in the PCSK1 gene that encodes PC1
were identified in human cases of early onset obesity [83]. In 1998
came the identification of mutations in both POMC [84] and MC4R
[85,86] that were linked to severe human obesity. In 2000, the deletion
of a single allele of Sim-1, a gene encoding a transcription factor
necessary for the normal development of the PVN produce obesity in
mice [87] and later in humans [88].
The one component of the central melanocortin pathway that when
disrupted does not clearly cause severe obesity is MC3R. Mc3r /
mice have a complicated phenotype, showing changes in body
composition with increased fat mass but reduced lean mass compared
to wild-type littermates despite being “hypophagic” and maintaining
normal metabolic rates [42,89]. However, mice lacking both MC3R and
MC4R become significantly heavier than Mc4r/ mice [42], indi-
cating that they serve non-redundant roles in regulating energy ho-
meostasis. No human MC3R mutations to date have been conclusively
linked to severe obesity, even if multiple smaller studies have reported
possible associations of MC3R variations with increased body weight
[90,91,92,93], although nowhere near the effect size of that seen with
mutations in MC4R. Taking into account all of the available evidence,
MC3R is less likely to be related to food intake and more likely to
revolve around nutrient partitioning. MC3R may thus serve a critical
role in ensuring the delicate balance between energy expenditure and
fat storage in the body [94].
The shared phenotype seen in monogenic non-syndromic obesity in-
cludes severe early onset obesity (before 5 years of age) with major
hyperphagia. Depending on the gene involved, patients can often be
affected by a number of endocrine abnormalities that includehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hypogonadism, growth hormone deficiency, hypothyroidism (for LEP
and LEPR), and corticotropic insufficiency (for POMC). A review re-
ported that across 88 patients with LEPR mutations, 100% had early
onset obesity (<5 years), 96% had hyperphagia, and 34% had one or
more pituitary hormone deficiencies [95]. In POMC variants, patients
display modifications in hair colour, adrenal dysfunction, and obesity
related to the absence of POMC-derived ligands for the melanocortin
receptors MC1R (aMSH), MC2R (ACTH), and MC4R (a and b MSH).
Since the proconvertase 1 (PC1) (encoded by PCSK1) enzyme is
involved in processing POMC, insulin, and proglucagon, some patients
also exhibit post-prandial hypoglycaemia and adrenal insufficiency
[84].
This list was recently extended with the discovery of variants in genes
that either regulate or are proposed to regulate the melanocortin
system. They include the MC4R regulator melanocortin receptor
accessory protein 2 (MRAP2) [96,97], adenylate cyclase 3 (ADCY3)
[98,99], and steroid coreceptor activator-1 (SRC-1) [100]. Other vari-
ants in genes acting on leptin/melanocortin signalling were reported
including brain-derived neurotrophic factor (BDNF) [101] and its re-
ceptor neurotrophic tyrosine kinase, receptor type 2 (NTRK2) [102], or
SH2B adaptor protein 1 (SH2B1) [103].
Hundreds of MC4R variants have been identified, leading to many
functional alterations that are sometimes inconsistent across subtypes
[104]. Heterozygous variants in MC4R are the most common and
frequently result in obesity with variable severity occurring at a later
age than in homozygous variant carriers. MC4R variants are found in
approximately 2%e5% of childhood and adult obesity [105] depending
on the population background and in up to 1% of the general popu-
lation with a BMI > 30 [106]. It cannot be excluded that due to
underdiagnoses, the frequency could increase to 30% in some pop-
ulations such as those with a high level of consanguinity [107].
Additionally, while most MC4R functional variants caused a reduction
in activity, a subset actually result in a gain of function (GoF), and these
GoF MC4R variants are associated with a lower risk of obesity and its
cardiometabolic complications in the general population [108]. Of note,
the degree to which a mutant receptor is dysfunctional as measured by
in vitro cAMP accumulation assays can actually predict the amount of
food eaten by the patient carrying that particular mutation at a test
meal [109]. All of this implies that MC4R, and hence the melanocortin
pathway more broadly, does not act in a binary on/off fashion, but is a
“tuneable” system.
As it turns out, the rheostatic nature of the melanocortin pathway in
regulating feeding behaviour is highly conserved, with naturally
occurring mutations in the pathway identified in a wide range of
different species depending on their selection pressure. For example,
studies in Labrador retrievers, which are known to be more food
motivated than other dog breeds, have found that anywhere from 20 to
25% carry a 14bp deletion in POMC that disrupts the b-MSH and b-
endorphin-coding sequences and is associated with greater food
motivation and increased body weight [26]. Certain pig breeds have
also been shown to carry MC4R missense mutations that are asso-
ciated with fatness, growth, and food intake traits [110]. MC4R mu-
tations have even contributed to the adaption and survival of blind
Mexican cavefish to nutrient-poor conditions found in underwater
caves [111].
Crucially, it is increasingly recognised that monogenic and polygenic
forms of obesity are not discrete entities but instead are on a spectrum
sharing at least some common biology, with the melanocortin pathwayMOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
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continued to discover more obesity-associated loci, an increasing
number of these loci harbour genes that sit within the pathway,
including MC4R [112,113], POMC [114], PCSK1 [115], SH2B1
[116,117], and BDNF [116] among others. Thus, while genetic
disruption of the pathway results in severe obesity, subtle variations in
or near these same genes in the pathway influence where one might
sit in the population distribution of BMI [118].
7. MELANOCORTIN LIGANDS
We summarise efforts to explore potential therapeutic applications for
treating obesity resulting from efforts to target the melanocortin
pathway. At the core of the pathway are the five G-protein coupled
receptors through which melanocortin peptides signal to affect their
diverse functions. Soon after their cloning, they were immediately
attractive “druggable” targets, and attempts to create more potent,
selective, and stable compounds resulted in the discovery of many
high-affinity ligands with differing specificities for the five receptors.
The toolbox of melanocortin ligands (Figure 2) include the endogenous
peptide agonists (ACTH, a-MSH, ß-MSH, and g2-MSH) and naturally
occurring antagonists (agouti and AgRP) as well as classic synthetic
peptides (MTII, SHU9119, and Ac-His-DPhe-Arg-Trp-NH2), clinically
approved melanocortin ligands (a-NDP-MSH/afamelanotide and bre-
melanotide), and setmelanotide, the FDA-approved agonist currently
undergoing further clinical trials. While melanocortin receptors have
been reported to signal through many different pathways, we focus on
ligands’ effects on intracellular cAMP levels, as this was the signal
transduction pathway that discovery of most ligands was based upon.
Tables 1 and 2 list reported binding and functional activities, respec-
tively, of these melanocortin ligands in cloned murine and human
MC1R, MC3R, MC4R, and MC5R. These are not exhaustive lists, but
are meant to illustrate the reported data. Since MC2R only interacts
with ACTH [119], MC2R is not further discussed. The pharmacology of
b-MSH, ACTH, and agouti is further separated based upon the
sequence used in the reported assays.
8. STRUCTURE-ACTIVITY RELATIONSHIPS OF ENDOGENOUS
LIGANDS
While melanocortin peptides are initially generated through cleavage
by prohormone convertases, the final processing amidation and
acetylation steps are crucial for their conversion into biologically active
moieties. The amidation process of peptides/hormones is not limited to
the processing of POMC so, as with proconvertase enzymes, this
cannot be regarded as being specific to POMC, and any associations
with a biological phenomenon are pleiotropic. However, acetylation is
relatively more specific to POMC processing. Acetylation is a common
modification of intracellular soluble proteins but is not common for
secreted peptides. Thus, acetylation of a-MSH represents a special
case in which the peptide’s activity can be modified [120,121]. The N-
terminus of a-MSH is acetylated by adding N- or NeO-acetyl groups,
with the non-acetylated form termed des-acetyl-a-MSH (des-a-MSH),
and acetylated forms, being mature forms of the peptide, are termed
a-MSH. This may be either mono-acetylated to form N-acetyl-a-MSH
or di-acetylated (N,O-diacetyl-a-MSH) (Figure 2). Acetylation of a-MSH
is hypothesised to enhance activity through increased biological sta-
bility. When the role of a-MSH as a brain peptide was recognised 40ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 2: Structures of the synthetic and endogenous human melanocortin ligands. The commonly hypothesised active sequences are highlighted in blue (endogenous agonists
and synthetic ligands) and red (endogenous antagonists).
Reviewyears ago, it was reported that it was more effective than its deace-
tylated form [122]. It was suggested that the difference in potency
could be because a-MSH is more resistant to degradation than the
deacetylated form.
Endogenous peptides share the tetrapeptide sequence His-Phe-Arg-
Trp (Figure 2, highlighted in blue). When the N-terminal of this tetra-
peptide is acetylated and the C-terminal is carboxyamidated, we obtain
a minimal sequence with binding and functional activity using classic
frog and lizard skin bioassays [123,124]. The full length of ACTH is 39
amino acids long, although ACTH(1e24) is hypothesised to be the
functional domain [125]. ACTH is the only known endogenous peptide
for MC2R, making it the only ligand that can stimulate all five MCRs
[119]. The first 13 residues of the N-terminal domain of ACTH are
cleaved and modified through N-terminal acetylation and C-terminal
carboxyamidation to produce a-MSH [122,126]. In MC1R, MC3R,
MC4R, and MC5R, a-MSH potencies range from nanomolar to sub-
nanomolar (Table 2). Unlike a-MSH, the b-MSH terminals are un-
modified. The binding affinities of b-MSH follow the general trend of
MC1R > MC3R  MC4R > MC5R, with nanomolar to sub-nanomolar
binding affinity at MC1R (Table 1). Three different forms of g-MSH6 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. Thave been described: g3-MSH (N-glycosylated 23 amino acid N-ter-
minal), g2-MSH (first 12 amino acids of g3-MSH), and g1-MSH (first 11
amino acids of g3-MSH with a carboxyamidated C-terminal) [127,128].
Although g2-MSH is selective for hMC3R over hMC4R and hMC5R
[129,130], g2-MSH is not selective for mMC3R over mMC5R [131]
(Table 2).
Distinctive to the melanocortin receptors compared to other G
protein-coupled receptors is the presence of two endogenous
antagonist peptides, agouti and AgRP. Agouti and AgRP contain a
tripeptide Arg-Phe-Phe sequence postulated to be important for
binding and functional activity located in their C-terminal domains
[20,132,133]. Agouti and AgRP possess five C-terminal disulphide
bonds, creating a similar cysteine knot conformation [20,133,134].
While in humans both are synthesised as 132 amino acid precursors,
the active form of agouti is agouti [23e50], [51e70], [71e100],
[101e132] and AgRP is the shorter AgRP (87-132) [135e137]. AgRP
is centrally expressed in the arcuate nucleus (partially overlapping
with the location of POMC neurons) and active at MC3R and MC4R
with nanomolar potencies, with a more variable response at the
MC5R depending on the sample’s purity, experimental conditions,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 e Binding affinities of melanocortin ligands in cloned murine and human melanocortin receptors.
Peptide Murine receptors (nM)a Human receptors (nM)
MC1R MC3R MC4R MC5R MC1R MC3R MC4R MC5R
















































b-MSH(5e22) 19.4 [168] 212 [170] 2.29 [181] 39.46 [181] 22.74 [181] 301.5 [181]
b-MSH(1e22) 0.89 [182] 10.64 [182] 8.18 [182] 76.90 [182]
g2-MSH 6.7 [168]
44(r) [169]











ACTH(1e24) 8.15(r) [166] 35.6(r) [166] 32.8 [166] 755 [166]




86.9 [172] 693 [179] 929 [180]
17,000 [172]














































Ac-His-DPhe-Arg-Trp-NH2 388 [191] 60%@100
mM [191]



































































AgoutiYY 15.3 [197] 14.1 [197] 1.8 [197]
AGRP 2.8 [198]c 0.66 [189]c
3.0 [198]c









a Values labelled with a (r) represent data from cloned rat receptors. Unlabelled numbers represent mouse receptors.
b Affinity b-MSH values were split depending on the sequence used. If a sequence was not provided in the paper, values are listed in the b-MSH row.
c The radiolabels [125I]MTII, [125I]SHU9119, and [125I]AGRP were used at their respective ligands as indicated in place of [125I]NDP-MSH.
d A mouse cell line natively expressing the MC1R was used.
e Values shown are IC50 values converted from pKi and pIC50 values reported in the source publication.and concentrations assayed (Table 1) [16,20,138,139]. While agouti
was first described as an antagonist at MC1R, it also interacts with
MC3R and MC4R with nanomolar potencies and with micromolar
affinity at MC5R (Table 1) [132,140,141e144]. AgRP also acts as an
inverse agonist at MC4R [132,140e144]. MC4R displays constitutive
receptor activity, meaning that in the absence of an endogenousMOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comagonist, it signals and affects, for instance, the gating of ion channels
[145], which is inhibited by AgRP. In POMC-null mice, administration
of AgRP has long-lasting effects on energy balance and increases
food intake, confirming its role in the absence of an agonist [146].
Besides being an inverse agonist, AgRP also acts as a biased agonist
that activates the MAPK signalling pathway [147].ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Table 2 e Functional pharmacology of the melanocortin ligands in cloned murine and human melanocortin receptors.
Peptide Murine receptorsa Human receptors
MC1R MC3R MC4R MC5R MC1R MC3R MC4R MC5R









































b-MSHb 12(r) [207] 4.24 [175] 1.59 [175] 6.62 [175] 23.7 [175]
209 [211]
b-MSH(5e22) 1.1 [168] 6.5 [170] 9.33 [181]































ACTH(1e24) 0.46(r) [207] 0.86 [202]
1.63 [209]
30 [211]
ACTH(1e39) 0.37 [203] 3.3 [168]
3.8(r) [169]
24(r) [206] 6.02 [170]
6.2(r) [207]
0.0083 [203] w1 [12] 0.68 [210]



































































































































Agouti 9.3 [222] 8.2 [222] 9.9 [222] 8.9 [222]
AgoutiYY 8.4 [197] 8.6 [197] 9.3 [197]




>100,000 [204] 8.4 [199] 8.20 [202]
8.6 [199]
8.76 [209]
a Values labelled with a (r) represent data from cloned rat receptors. Unlabelled numbers represent mouse receptors.
b Potency EC50 b-MSH values were split depending on the sequence used. If a sequence was not provided in the paper, values are listed in the b-MSH row.
c Values labelled with a (L) were reported using a low receptor expression.
d Values shown were converted from pEC50 values reported in the source publication.
Review9. SYNTHETIC LIGANDS
Synthetic ligands for MCRs have been discovered from structuree
activity relationship studies of endogenous melanocortin ligands. The
conversion of Met(4) into norleucine or Nle(4) and Phe(7) to DPhe(7) in
a-MSH results in the peptide [Nle4,DPhe7]a-MSH (Figure 2), also
known as NDP-MSH, melanotan I (MTI), and afamelanotide (approved
to treat erythropoietic protoporphyria) [148]. First reported in 1980
[149], NDP-MSH has nanomolar to sub-nanomolar potencies in MC1R,8 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. TMC3R, MC4R, and MC5R (Table 2). The tetrapeptide Ac-His-DPhe-Arg-
Trp-NH2 is the minimum NDP-MSH sequence that maintains nano-
molar agonist potency in mouse MC1R, MC3R, MC4R, and MC5R [150]
(Table 2). Melanotan II (MTII) maintains Nle and DPhe substitutions of
NDP-MSH, but cycles through a lactam bridge between substituted
Glu(5) to Asp(5) and Gly(10) to Lys(10) of NDP-MSH and truncations of
residues 1e3 and 11e13 (NDP-MSH numbering; Figure 2) [151,152].
MTII is a non-selective melanocortin agonist with nanomolar to sub-
nanomolar potencies [151,152] (Table 2). Bremelanotide (PT-141) ishis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 3 e MC4R agonists studied in human clinical studies for various indications.
MC4R agonist, sponsor Molecule type Indication Route of
administration









0.25 mg/kg, bolus Increased cardiovascular (CV)











Subcutaneous Efficacious in both
indications










Small molecule MED and post-
menopausal HSDD




Not disclosed Unknown [225]
MK-0493,
Merck





Obesity Subcutaneous infusion No efficacy observed 0.5, 0.15, 0.45, and
1 mg infused over
24 h
0.15, 0.45, 1, and
2 mg/day for 7 days





12 amino acid peptide
with a modified lipid
chain
















Genetic obesity Subcutaneous Efficacy established in
completed phase II
and phase III studies
1e3 mg bolus per day No increase in CV activity.
Selected common side effects
can include hyperpigmentation,
nausea/vomiting, penile
erection, and injection site
reactions












































Reviewa cyclic lactam that differs from MTII by one functional group (a C-
terminal carboxylic acid vs carboxamide) reported to possess similar
agonist potency compared to MTII (Table 2) and is approved for treating
hypoactive sexual desire disorder [153,154]. While it is well known
that MC4R agonists acting centrally can trigger sexual arousal
behaviour in males and females, the details of pathway mechanisms
mediating this response still remain largely unknown [155,156]. Within
the MTII scaffold, substituting DPhe(7) with D-20-naphthylalanine or
DNal(20)(7) results in SHU9119 [157] (Figure 2). SHU9119 is a nano-
molar to sub-nanomolar agonist in MC1R and MC5R with antagonist
activity in MC3R and MC4R [157] (Table 2). SHU9119 also possesses
partial agonist efficacy in MC3R. In 2020, the 2.8 Å crystal structure of
hMC4R bound to the SHU9119 cyclic peptide antagonist was reported
[158], revealing the importance of the Caþ2 ion for melanocortin
receptor function as initially observed in the 1980s [159].
10. TARGETING THE MELANOCORTIN SYSTEM AS AN OBESITY
THERAPY
For over 20 years, oral small molecules and injectable peptide agonists
of MC4R have been clinically evaluated for treating obesity (oral small
molecule MK-0493 (Merck) and peptide agonists LY2112688 (Eli Lilly),
MC4-NN-0453 (Novo Nordisk), AZD2820 (AstraZeneca), and setme-
lanotide (Rhythm Pharmaceuticals)). Most of these compounds pro-
duced to develop therapeutics for treating obesity failed in the clinic
despite preclinical efficacy. Table 3 provides a list of these compounds
along with the dose ranges explored in clinical studies and the
observed side effects. Failure of most of these MC4R agonist drug
candidates has been variably ascribed to the: i) lack of human efficacy,
ii) significant cardiovascular adverse side effects, iii) occurrences of
nausea and vomiting, and iv) stimulation of sexual arousal.
The exception to this to date has been a cyclic octapeptide setmela-
notide, which received FDA approval in 2020 for treating obesity
caused by genetic defects in POMC, LEPR, or PCSK1. Setmelanotide
did not elicit undesirable cardiovascular effects [5,104,160,161,162].
Minor adverse effects that were well tolerated are listed in Table 3
Interestingly, an older study demonstrated that in obese controls not
known to have these mutations, setmelanotide showed initial evidence
of moderate weight loss over a 28-day treatment period (0.99 kg/wk;
P¼< 0.0001). In this study, weight loss in subjects with heterozygous
MC4R deficiency leading to only one remaining wild-type MC4R allele
as the target of setmelanotide tended to have significant weight loss
(0.6 kg/wk; P ¼ 0.09) [104]. The efficacy of setmelanotide was more
pronounced in subjects with biallelic POMC and LEPR deficiency
obesity, with 80% of POMC-deficient subjects and 45% of LEPR-
deficient subjects losing >10% of their weight in approximately one
year. This weight loss was also accompanied by a significant decrease
in hunger scores (27.1%, P ¼ 0.0005 in POMC deficiency
and 43.7%, P ¼< 0.0001 in LERP deficiency) [5]. Based on these
evaluations, it has become clear that potency at MC4R associated with
clinical anti-obesity benefits can be attained by peptide ligands as
exemplified by setmelanotide and that nano-molar plasma concen-
trations suffice to elicit clinical benefits (setmelanotide EC50 at MC4R is
w0.3 nM). One of the possible reasons setmelanotide may differ from
other clinically tested MC4R agonists is that its activated MC4R signal
transduction pathway differs from a-MSH. GoF MC4R variants that
were associated with significantly lower BMI, for instance, exhibit a
signalling bias toward b-arrestin recruitment and increased mitogen-
activated protein kinase pathway activation [108]. Setmelanotide also
potently induces PLC-b activation through MC4R, likely via Gaq acti-
vation. In the PLC assay (through the NFAT reporter gene) that captures10 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. Tthis pathway’s activity, 100 nM of AgRP could not antagonise
setmelanotide-stimulated PLC activation while stimulation by a-MSH
was antagonised. MC4R displays biased agonism, whereby setmela-
notide also potently activates the PLC pathway. Determining NFAT
signalling after MC4R stimulation revealed an approximately 100-fold
higher efficacy of setmelanotide compared with the endogenous
agonist. These insights may help advance the ability to target the
MC4R pathway and continue to develop next-generation MC4R ago-
nists for treating obesity.
Regarding treatingmore common types of obesity, Wilding et al. recently
described the therapeutic benefits of a once-weekly injection of the GLP-
1R agonist semaglutide to treat general obesity [163]. Interestingly, in
rodent experiments, the GLP-1R agonist liraglutide and setmelanotide
were shown to have additive effects on glycaemic control, weight loss,
and cholesterol metabolism, indicating their independent metabolic ef-
fects [164]. Clinical studies also demonstrated the potential to activate
the MC4R pathway for weight loss in the general obese population,
although more clinical research is needed [104].
11. CONCLUDING REMARKS
The discovery of MC4R drugs to treat obesity exemplifies how today’s
molecular neuroscience and circuit neurophysiology contributes to the
development of circuit-targeted pharmaceuticals. The MC4R agonist
setmelanotide received FDA approval in 2020 for treating subjects with
specific genetic defects upstream of MC4R, resulting in obesity.
Unravelling the genetics of a disorder, dissecting the precise role of
genes in a physiological process, and studying the molecular phar-
macology of drug targets brought a new drug to the market for a
complex disorder. This drug discovery process is one of the first ex-
amples of a new era in finding drugs for complex disorders such as
brain diseases, which in the case of setmelanotide took 25 years to go
from identifying critical genes associated with clinical symptoms to an
approved drug.
FUNDING
G.S.H.Y. is supported by the UK Medical Research Council (MRC
Metabolic Diseases Unit (MC_UU_00014/1) and MRC project grant
(MR/S026193/1). A.M.S. is supported by a UK MRC project grant (MR/
S026193/1). S.L is supported by the Centre National la Recherche
Scientifique (CNRS), the Université de Paris, the Modern Diet and
Physiology Research Center (MDPRC), the National Research Agency
National Research Agency (ANR-15-CE14-0030-01: Nutritpathos) and
the Foundation pour la Recherche Médicale (FRM). D.H.M.C receives
support the National Research Agency National Research Agency
(ANR-15-CE14-0030-01: Nutritpathos). K.C. is supported by the Fon-
dation pour la Recherche médicale (FRM). C.H.L, Z.M.K, M.D.E and
C.M.L are funded by the NIH NIDDK (1R01DK108893). S.E.S and
M.A.C. are funded by an Australian NHMRC grant (1163341). R.A.H.A.
is supported by the European Union Seventh Framework Programme
(grant number 607310; Nudge-it), the Netherlands Organisation for
Scientific Research (grant numbers ALWOP.137 and OCENW.-
KLEIN.071), the Swedish Research Council (2018e02588), and ERA-
NET NEURON (MiGBAN).
AUTHOR CONTRIBUTIONS
G.S.H.Y. and R.A.H.A. conceived and assembled this consortium re-
view. All of the other authors drafted their respective sections and
commented on the final manuscript.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
CONFLICT OF INTEREST
Shubh Sharma is an employee and shareholder of Rhythm Pharmaceuticals. Lex Van
der Ploeg served as CSO of Rhythm Pharmaceuticals from 2011 to 2019 and since
2019 has been an advisor to Rhythm Pharmaceuticals and shareholder. Rhythm
Pharmaceuticals is a NASDAQ publicly traded company (RYTM). KC is a primary
investigator for several setmelanotide trials funded by Rhythm Pharmaceuticals in
France, but this does not alter this review’s content. All of the other authors have no
conflicts of interest to declare.
REFERENCES
[1] Stunkard, A.J., Foch, T.T., Hrubec, Z., 1986. A twin study of human obesity.
Journal of the American Medical Association 256(1):51e54.
[2] Stunkard, A.J., Harris, J.R., Pedersen, N.L., McClearn, G.E., 1990. The body-
mass index of twins who have been reared apart. New England Journal of
Medicine 322(21):1483e1487.
[3] Bertagna, X., 1994. Proopiomelanocortin-derived peptides. Endocrinology
and Metabolism Clinics of North America 23(3):467e485.
[4] Cone, R.D., 2006. Studies on the physiological functions of the melanocortin
system. Endocrine Reviews 27(7):736e749.
[5] Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W.K.,
Connors, H., et al., 2020. Efficacy and safety of setmelanotide, an MC4R
agonist, in individuals with severe obesity due to LEPR or POMC deficiency:
single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes &
Endocrinology 8(12):960e970.
[6] Ferrari, W., 1958. Behavioural changes in animals after intracisternal injec-
tion with adrenocorticotrophic hormone and melanocyte-stimulating hor-
mone. Nature 181(4613):925e926.
[7] Gee, C.E., Chen, C.L., Roberts, J.L., Thompson, R., Watson, S.J., 1983.
Identification of proopiomelanocortin neurones in rat hypothalamus by in situ
cDNA-mRNA hybridization. Nature 306(5941):374e376.
[8] Tatro, J.B., 1990. Melanotropin receptors in the brain are differentially
distributed and recognize both corticotropin and alpha-melanocyte stimu-
lating hormone. Brain Research 536(1e2):124e132.
[9] Dewied, D., 1964. Influence of anterior pituitary on avoidance learning and
escape behavior. American Journal of Physiology 207:255e259.
[10] Vergoni, A.V., Poggioli, R., Bertolini, A., 1986. Corticotropin inhibits food
intake in rats. Neuropeptides 7(2):153e158.
[11] Mountjoy, K.G., Robbins, L.S., Mortrud, M.T., Cone, R.D., 1992. The cloning
of a family of genes that encode the melanocortin receptors. Science
257(5074):1248e1251.
[12] Gantz, I., Konda, Y., Tashiro, T., Shimoto, Y., Miwa, H., Munzert, G., et al.,
1993. Molecular cloning of a novel melanocortin receptor. Journal of Bio-
logical Chemistry 268(11):8246e8250.
[13] Roselli-Rehfuss, L., Mountjoy, K.G., Robbins, L.S., Mortrud, M.T., Low, M.J.,
Tatro, J.B., et al., 1993. Identification of a receptor for gamma melanotropin
and other proopiomelanocortin peptides in the hypothalamus and limbic
system. Proceedings of the National Academy of Sciences of the United
States of America 90(19):8856e8860.
[14] Gantz, I., Shimoto, Y., Konda, Y., Miwa, H., Dickinson, C.J., Yamada, T.,
1994. Molecular cloning, expression, and characterization of a fifth mela-
nocortin receptor. Biochemical and Biophysical Research Communications
200(3):1214e1220.
[15] Robbins, L.S., Nadeau, J.H., Johnson, K.R., Kelly, M.A., Roselli-Rehfuss, L.,
Baack, E., et al., 1993. Pigmentation phenotypes of variant extension locus
alleles result from point mutations that alter MSH receptor function. Cell
72(6):827e834.MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com[16] Lu, D., Willard, D., Patel, I.R., Kadwell, S., Overton, L., Kost, T., et al., 1994.
Agouti protein is an antagonist of the melanocyte-stimulating-hormone re-
ceptor. Nature 371(6500):799e802.
[17] Bultman, S.J., Michaud, E.J., Woychik, R.P., 1992. Molecular characterization
of the mouse agouti locus. Cell 71(7):1195e1204.
[18] Miller, M.W., Duhl, D.M., Vrieling, H., Cordes, S.P., Ollmann, M.M.,
Winkes, B.M., et al., 1993. Cloning of the mouse agouti gene predicts a
secreted protein ubiquitously expressed in mice carrying the lethal yellow
mutation. Genes & Development 7(3):454e467.
[19] Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J., Cone, R.D., 1997. Role of
melanocortinergic neurons in feeding and the agouti obesity syndrome.
Nature 385(6612):165e168.
[20] Ollmann, M.M., Wilson, B.D., Yang, Y.K., Kerns, J.A., Chen, Y., Gantz, I.,
et al., 1997. Antagonism of central melanocortin receptors in vitro and in vivo
by agouti-related protein. Science 278(5335):135e138.
[21] Cowley, M.A., Pronchuk, N., Fan, W., Dinulescu, D.M., Colmers, W.F.,
Cone, R.D., 1999. Integration of NPY, AGRP, and melanocortin signals in the
hypothalamic paraventricular nucleus: evidence of a cellular basis for the
adipostat. Neuron 24(1):155e163.
[22] Cone, R.D., 2005. Anatomy and regulation of the central melanocortin sys-
tem. Nature Neuroscience 8(5):571e578.
[23] Fan, W., Ellacott, K.L.J., Halatchev, I.G., Takahashi, K., Yu, P., Cone, R.D.,
2004. Cholecystokinin-mediated suppression of feeding involves the brain-
stem melanocortin system. Nature Neuroscience 7(4):335e336.
[24] Ellacott, K.L., Halatchev, I.G., Cone, R.D., 2006. Characterization of leptin-
responsive neurons in the caudal brainstem. Endocrinology 147(7):3190e3195.
[25] Lee, Y.S., Challis, B.G., Thompson, D.A., Yeo, G.S.H., Keogh, J.M.,
Madonna, M.E., et al., 2006. A POMC variant implicates beta-melanocyte-
stimulating hormone in the control of human energy balance. Cell Metabolism
3(2):135e140.
[26] Raffan, E., Dennis, R.J., O’Donovan, C.J., Becker, J.M., Scott, R.A.,
Smith, S.P., et al., 2016. A deletion in the canine POMC gene is associated
with weight and appetite in obesity-prone labrador retriever dogs. Cell
Metabolism 23(5):893e900.
[27] Berglund, E.D., Vianna, C.R., Donato Jr., J., Kim, M.H., Chuang, J., Lee, C.E.,
et al., 2012. Direct leptin action on POMC neurons regulates glucose ho-
meostasis and hepatic insulin sensitivity in mice. Journal of Clinical Inves-
tigation 122(3):1000e1009.
[28] Dunbar, J.C., Lu, H., 2000. Proopiomelanocortin (POMC) products in the
central regulation of sympathetic and cardiovascular dynamics: studies on
melanocortin and opioid interactions. Peptides 21(2):211e217.
[29] Faulkner, L.D., Dowling, A.R., Stuart, R.C., Nillni, E.A., Hill, J.W., 2015. Reduced
melanocortin production causes sexual dysfunction in male mice with POMC
neuronal insulin and leptin insensitivity. Endocrinology 156(4):1372e1385.
[30] Parton, L.E., Dowling, A.R., Stuart, R.C., Nillni, E.A., Hill, J.W., 2007. Glucose
sensing by POMC neurons regulates glucose homeostasis and is impaired in
obesity. Nature 449(7159):228e232.
[31] Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sørensen, J., Cowley, M.A.,
Dalbøge, L.S., et al., 2014. The arcuate nucleus mediates GLP-1 receptor
agonist liraglutide-dependent weight loss. Journal of Clinical Investigation
124(10):4473e4488.
[32] Cowley, M.A., Smith, Ro.G., Diano, S., Tschöp, M., Pronchuk, N., Grove, K.L.,
et al., 2003. The distribution and mechanism of action of ghrelin in the CNS
demonstrates a novel hypothalamic circuit regulating energy homeostasis.
Neuron 37(4):649e661.
[33] Batterham, R.L., Cowley, M.A., Small, C.J., Herzog, H., Cohen, M.A.,
Dakin, C.L., et al., 2002. Gut hormone PYY(3-36) physiologically inhibits food
intake. Nature 418(6898):650e654.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 11
Review[34] Ghamari-Langroudi, M., Colmers, W.F., Cone, R.D., 2005. PYY3-36 inhibits
the action potential firing activity of POMC neurons of arcuate nucleus
through postsynaptic Y2 receptors. Cell Metabolism 2(3):191e199.
[35] Marks, D.L., Ling, N., Cone, R.D., 2001. Role of the central melanocortin
system in cachexia. Cancer Research 61(4):1432e1438.
[36] Scarlett, J.M., Bowe, D.D., Zhu, X., Batra, A.K., Grant, W.F., Marks, D.L.,
2010. Genetic and pharmacologic blockade of central melanocortin signaling
attenuates cardiac cachexia in rodent models of heart failure. Journal of
Endocrinology 206(1):121e130.
[37] Dodd, G.T., Michael, N.J., Lee-Young, R.S., Mangiafico, S.P., Pryor, J.T.,
Munder, A.C., et al., 2018. Insulin regulates POMC neuronal plasticity to
control glucose metabolism. Elife 7.
[38] Hill, J.W., Elias, C.F., Fukuda, M., Williams, K.W., Berglund, E.D.,
Holland, W.L., et al., 2010. Direct insulin and leptin action on pro-opiome-
lanocortin neurons is required for normal glucose homeostasis and fertility.
Cell Metabolism 11(4):286e297.
[39] Plum, L., Schubert, M., Bruning, J.C., 2005. The role of insulin receptor
signaling in the brain. Trends in Endocrinology and Metabolism 16(2):59e65.
[40] Wu, Q., Lemus, M.B., Stark, R., Bayliss, J.A., Reichenbach, A., Lockie, S.H.,
et al., 2014. The temporal pattern of cfos activation in hypothalamic, cortical,
and brainstem nuclei in response to fasting and refeeding in male mice.
Endocrinology 155(3):840e853.
[41] Chen, A.S., Metzger, J.M., Trumbauer, M.E., Guan, X.M., Yu, H., Frazier, E.G.,
et al., 2000. Role of the melanocortin-4 receptor in metabolic rate and food
intake in mice. Transgenic Research 9(2):145e154.
[42] Chen, A.S., Marsh, D.J., Trumbauer, M.E., Frazier, E.G., Guan, X.M., Yu, H.,
et al., 2000. Inactivation of the mouse melanocortin-3 receptor results in
increased fat mass and reduced lean body mass. Nature Genetics 26(1):97e
102.
[43] Balthasar, N., Dalgaard, L.T., Lee, C.E., Yu, J., Funahashi, H., Williams, T.,
et al., 2005. Divergence of melanocortin pathways in the control of food
intake and energy expenditure. Cell 123(3):493e505.
[44] Garfield, A.S., Li, C., Madara, J.C., Shah, B.P., Webber, E., Steger, J.S., et al.,
2015. A neural basis for melanocortin-4 receptor-regulated appetite. Nature
Neuroscience 18(6):863e871.
[45] Shah, B.P., Vong, L., Olson, D.P., Koda, S., Krashes, M.J., Ye, C., et al., 2014.
MC4R-expressing glutamatergic neurons in the paraventricular hypothalamus
regulate feeding and are synaptically connected to the parabrachial nucleus.
Proceedings of the National Academy of Sciences of the United States of
America 111(36):13193e13198.
[46] Kim, M.S., Rossi, M., Abusnana, S., Sunter, D., Morgan, D.G., J Small, C.,
et al., 2000. Hypothalamic localization of the feeding effect of agouti-related
peptide and alpha-melanocyte-stimulating hormone. Diabetes 49(2):177e
182.
[47] de Backer, M.W., la Fleur, S.E., Brans, M.A.D., van Rozen, A.J.,
Luijendijk, M.C.M., Merkestein, M., et al., 2011. Melanocortin receptor-
mediated effects on obesity are distributed over specific hypothalamic re-
gions. International Journal of Obesity 35(5):629e641.
[48] Fenselau, H., Campbell, J.N., Verstegen, A.M.J., Madara, J.C., Xu, J.,
Shah, B.P., et al., 2017. A rapidly acting glutamatergic ARC->PVH satiety
circuit postsynaptically regulated by alpha-MSH. Nature Neuroscience 20(1):
42e51.
[49] Kwon, E., Jo, Y.H., 2020. Activation of the ARC(POMC)->MeA projection
reduces food intake. Frontiers in Neural Circuits 14:595783.
[50] Rossi, J., Balthasar, N., Olson, D., Scott, M., Berglund, E., Lee, C.E., et al.,
2011. Melanocortin-4 receptors expressed by cholinergic neurons regulate
energy balance and glucose homeostasis. Cell Metabolism 13(2):195e204.
[51] Pei, H., Patterson, C.M., Sutton, A.K., Burnett, K.H., Myers Jr., M.G.,
Olson, D.P., 2019. Lateral hypothalamic Mc3R-expressing neurons modulate
locomotor activity, energy expenditure, and adiposity in male mice. Endo-
crinology 160(2):343e358.12 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. T[52] Bewick, G.A., Gardiner, J.V., Dhillo, W.S., Kent, A.S., White, N.E., Webster, Z.,
et al., 2005. Post-embryonic ablation of AgRP neurons in mice leads to a
lean, hypophagic phenotype. The FASEB Journal 19(12):1680e1682.
[53] Gropp, E., Shanabrough, M., Borok, E., Xu, A.W., Janoschek, R., Buch, T.,
et al., 2005. Agouti-related peptide-expressing neurons are mandatory for
feeding. Nature Neuroscience 8(10):1289e1291.
[54] Luquet, S., Perez, F.A., Hnasko, T.S., Palmiter, R.D., 2005. NPY/AgRP neu-
rons are essential for feeding in adult mice but can be ablated in neonates.
Science 310(5748):683e685.
[55] Aponte, Y., Atasoy, D., Sternson, S.M., 2011. AGRP neurons are sufficient to
orchestrate feeding behavior rapidly and without training. Nature Neurosci-
ence 14(3):351e355.
[56] Krashes, M.J., Koda, S., Ye, C.P., Rogan, S.C., Adams, A.C., Cusher, D.S.,
et al., 2011. Rapid, reversible activation of AgRP neurons drives feeding
behavior in mice. Journal of Clinical Investigation 121(4):1424e1428.
[57] Horvath, T.L., Bechmann, I., Naftolin, F., Kalra, S.P., Leranth, C., 1997.
Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate
nucleus: GABAergic and non-GABAergic subpopulations. Brain Research
756(1e2):283e286.
[58] Wu, Q., Boyle, M.P., Palmiter, R.D., 2009. Loss of GABAergic signaling by
AgRP neurons to the parabrachial nucleus leads to starvation. Cell 137(7):
1225e1234.
[59] Wu, Q., Howell, M.P., Cowley, M.A., Palmiter, R.D., 2008. Starvation after
AgRP neuron ablation is independent of melanocortin signaling. Proceedings
of the National Academy of Sciences of the United States of America 105(7):
2687e2692.
[60] Betley, J.N., Cao, Z.F.H., Ritola, K.D., Sternson, S.M., 2013. Parallel,
redundant circuit organization for homeostatic control of feeding behavior.
Cell 155(6):1337e1350.
[61] Krashes, M.J., Shah, B.P., Koda, S., Lowell, B.B., 2013. Rapid versus delayed
stimulation of feeding by the endogenously released AgRP neuron mediators
GABA, NPY, and AgRP. Cell Metabolism 18(4):588e595.
[62] Broberger, C., Johansen, J., Johansson, C., Schalling, M., Hökfelt, T., 1998.
The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in
normal, anorectic, and monosodium glutamate-treated mice. Proceedings of
the National Academy of Sciences of the United States of America 95(25):
15043e15048.
[63] Atasoy, D., Betley, J.N., Su, H.H., Sternson, S.M., 2012. Deconstruction of a
neural circuit for hunger. Nature 488(7410):172e177.
[64] Wu, Q., Clark, M.S., Palmiter, R.D., 2012. Deciphering a neuronal circuit that
mediates appetite. Nature 483(7391):594e597.
[65] Carter, M.E., Soden, M.E., Zweifel, L.S., Palmiter, R.D., 2013. Genetic
identification of a neural circuit that suppresses appetite. Nature 503(7474):
111e114.
[66] Campos, C.A., Bowen, A.J., Schwartz, M.W., Palmiter, R.D., 2016. Para-
brachial CGRP neurons control meal termination. Cell Metabolism 23(5):
811e820.
[67] Carter, M.E., Han, S., Palmiter, R.D., 2015. Parabrachial calcitonin gene-
related peptide neurons mediate conditioned taste aversion. Journal of
Neuroscience 35(11):4582e4586.
[68] Essner, R.A., Smith, A.G., Jamnik, A.A., Ryba, A.R., Trutner, Z.D.,
Carter, M.E., 2017. AgRP neurons can increase food intake during conditions
of appetite suppression and inhibit anorexigenic parabrachial neurons.
Journal of Neuroscience 37(36):8678e8687.
[69] Henry, F.E., Sugino, K., Tozer, A., Branco, T., Sternson, S.M., 2015. Cell type-
specific transcriptomics of hypothalamic energy-sensing neuron responses to
weight-loss. Elife 4.
[70] Betley, J.N., Xu, S.J., Cao, Z.F.H., Gong, R., Magnus, C.J., Yu, Y., et al., 2015.
Neurons for hunger and thirst transmit a negative-valence teaching signal.
Nature 521(7551):180e185.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
[71] Chen, Y., Lin, Y.C., Kuo, T.W., Knight, Z.A., 2015. Sensory detection of food
rapidly modulates arcuate feeding circuits. Cell 160(5):829e841.
[72] Mandelblat-Cerf, Y., Ramesh, R.N., Burgess, C.R., Patella, P., Yang, Z.F.,
Lowell, B.B., et al., 2015. Arcuate hypothalamic AgRP and putative POMC
neurons show opposite changes in spiking across multiple timescales. Elife
4.
[73] Bai, L., Mesgarzadeh, S., Ramesh, K.S., Huey, E.L., Liu, Y., Gray, L.A., et al.,
2019. Genetic identification of vagal sensory neurons that control feeding.
Cell 179(5):1129e1143 e23.
[74] Beutler, L.R., Chen, Y.M., Ahn, J.S., Lin, Y.C., Essner, R.A., Knight, Z.A.,
2017. Dynamics of gut-brain communication underlying hunger. Neuron
96(2):461e475 e5.
[75] Goldstein, N., McKnight, A.D., Carty, J.R.E., Arnold, M., Betley, J.N.,
Alhadeff, A.L., 2021. Hypothalamic detection of macronutrients via multiple
gut-brain pathways. Cell Metabolism.
[76] Su, Z., Alhadeff, A.L., Betley, J.N., 2017. Nutritive, post-ingestive signals are
the primary regulators of AgRP neuron activity. Cell Reports 21(10):2724e
2736.
[77] Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J.M.,
1994. Positional cloning of the mouse obese gene and its human homologue.
Nature 372(6505):425e432.
[78] Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H.,
Wareham, N.J., et al., 1997. Congenital leptin deficiency is associated with
severe early-onset obesity in humans. Nature 387(6636):903e908.
[79] Clement, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., et al.,
1998. A mutation in the human leptin receptor gene causes obesity and
pituitary dysfunction. Nature 392(6674):398e401.
[80] Friedman, J.M., Halaas, J.L., 1998. Leptin and the regulation of body weight
in mammals. Nature 395(6704):763e770.
[81] Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-
Flier, E., et al., 1996. Role of leptin in the neuroendocrine response to fasting.
Nature 382(6588):250e252.
[82] Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang, Q.,
Berkemeier, L.R., et al., 1997. Targeted disruption of the melanocortin-4
receptor results in obesity in mice. Cell 88(1):131e141.
[83] Jackson, R.S., Creemers, J.W., Ohagi, S., Raffin-Sanson, M.L., Sanders, L.,
Montague, C.T., et al., 1997. Obesity and impaired prohormone processing
associated with mutations in the human prohormone convertase 1 gene.
Nature Genetics 16(3):303e306.
[84] Krude, H., Biebermann, H., Luck, W., Horn, R., Brabant, G., Grüters, A., 1998.
Severe early-onset obesity, adrenal insufficiency and red hair pigmentation
caused by POMC mutations in humans. Nature Genetics 19(2):155e157.
[85] Vaisse, C., Clement, K., Guy-Grand, B., Froguel, P., 1998. A frameshift
mutation in human MC4R is associated with a dominant form of obesity.
Nature Genetics 20(2):113e114.
[86] Yeo, G.S.H., Farooqi, I.S., Aminian, S., Halsall, D.J., Stanhope, R.G.,
O’Rahilly, S., 1998. A frameshift mutation in MC4R associated with domi-
nantly inherited human obesity. Nature Genetics 20(2):111e112.
[87] Michaud, J.L., Boucher, F., Melnyk, A., Gauthier, F., Goshu, E., Lévy, E.,
et al., 2001. Sim1 haploinsufficiency causes hyperphagia, obesity and
reduction of the paraventricular nucleus of the hypothalamus. Human Mo-
lecular Genetics 10(14):1465e1473.
[88] Ramachandrappa, S., Raimondo, A., Cali, A.M.G., Keogh, J.M., Henning, El.,
Saeed, S., et al., 2013. Rare variants in single-minded 1 (SIM1) are asso-
ciated with severe obesity. Journal of Clinical Investigation 123(7):3042e
3050.
[89] Butler, A.A., Kesterson, R.A., Khong, K., Cullen, M.J., Pelleymounter, M.A.,
Dekoning, J., et al., 2000. A unique metabolic syndrome causes obesity in
the melanocortin-3 receptor-deficient mouse. Endocrinology 141(9):3518e
3521.MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com[90] Demidowich, A.P., Jun, J.Y., Yanovski, J.A., 2017. Polymorphisms and
mutations in the melanocortin-3 receptor and their relation to human obesity.
Biochimica et Biophysica Acta - Molecular Basis of Disease 1863(10 Pt A):
2468e2476.
[91] Lee, Y.S., Poh, L.K., Loke, K.Y., 2002. A novel melanocortin 3 receptor gene
(MC3R) mutation associated with severe obesity. Journal of Clinical Endo-
crinology & Metabolism 87(3):1423e1426.
[92] Mencarelli, M., Dubern, B., Alili, R., Maestrini, S., Benajiba, L., Tagliaferri, M.,
et al., 2011. Rare melanocortin-3 receptor mutations with in vitro functional
consequences are associated with human obesity. Human Molecular Ge-
netics 20(2):392e399.
[93] Zegers, D., Beckers, S., de Freitas, F., Peeters, Ar.V., Mertens, I.L.,
Verhulst, St.L., et al., 2011. Identification of three novel genetic variants in
the melanocortin-3 receptor of obese children. Obesity 19(1):152e159.
[94] Ghamari-Langroudi, M., Cakir, I., Lippert, R.N., Sweeney, P., Litt, M.J.,
Ellacott, K.L.J., et al., 2018. Regulation of energy rheostasis by the mela-
nocortin-3 receptor. Science Advances 4(8):eaat0866.
[95] Kleinendorst, L., Abawi, O., van der Kamp, H.J., Alders, M., Meijers-
Heijboer, H.E.J., van Rossum, E.F.C., et al., 2020. Leptin receptor deficiency:
a systematic literature review and prevalence estimation based on population
genetics. European Journal of Endocrinology 182(1):47e56.
[96] Asai, M., Ramachandrappa, S., Joachim, M., Shen, Y., Zhang, R.,
Nuthalapati, N., et al., 2013. Loss of function of the melanocortin 2 receptor
accessory protein 2 is associated with mammalian obesity. Science
341(6143):275e278.
[97] Baron, M., Maillet, J., Huyvaert, M., Dechaume, A., Boutry, R., Loiselle, H.,
et al., 2019. Loss-of-function mutations in MRAP2 are pathogenic in hy-
perphagic obesity with hyperglycemia and hypertension. Nature Medicine
25(11):1733e1738.
[98] Grarup, N., Moltke, I., Andersen, M.K., Dalby, M., Vitting-Seerup, K., Kern, T.,
et al., 2018. Loss-of-function variants in ADCY3 increase risk of obesity and
type 2 diabetes. Nature Genetics 50(2):172e174.
[99] Saeed, S., Bonnefond, A., Tamanini, F., Mirza, M.U., Manzoor, J.,
Janjua, Q.M., et al., 2018. Loss-of-function mutations in ADCY3 cause
monogenic severe obesity. Nature Genetics 50(2):175e179.
[100] Yang, Y., van der Klaauw, A.A., Zhu, L.G., Cacciottolo, T.M., He, Y.L.,
Stadler, L.K.J., et al., 2019. Steroid receptor coactivator-1 modulates the
function of Pomc neurons and energy homeostasis. Nature Communications
10(1):1718.
[101] Gray, J., Yeo, G.S.H., Cox, J.J., Morton, J., Adlam, A.L.R., Keogh, J.M., et al.,
2006. Hyperphagia, severe obesity, impaired cognitive function, and hyper-
activity associated with functional loss of one copy of the brain-derived
neurotrophic factor (BDNF) gene. Diabetes 55(12):3366e3371.
[102] Yeo, G.S.H., Hung, C.C.C., Rochford, J., Keogh, J., Gray, J.,
Sivaramakrishnan, S., et al., 2004. A de novo mutation affecting human TrkB
associated with severe obesity and developmental delay. Nature Neurosci-
ence 7(11):1187e1189.
[103] Doche, M.E., Bochukova, E.G., Su, H.Wen., Pearce, L.R., Keogh, J.M.,
Henning, E., et al., 2012. Human SH2B1 mutations are associated with
maladaptive behaviors and obesity. Journal of Clinical Investigation 122(12):
4732e4736.
[104] Collet, T.H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J.M., de
Oliveira, E.M., et al., 2017. Evaluation of a melanocortin-4 receptor (MC4R)
agonist (Setmelanotide) in MC4R deficiency. Molecular Metabolism 6(10):
1321e1329.
[105] Kuhnen, P., Krude, H., Biebermann, H., 2019. Melanocortin-4 receptor sig-
nalling: importance for weight regulation and obesity treatment. Trends in
Molecular Medicine 25(2):136e148.
[106] Alharbi, K.K., Spanakis, E., Tan, K., Smith, M.J., Aldahmesh, M.A.,
O’Dell, S.D., et al., 2007. Prevalence and functionality of paucimorphic andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 13
Reviewprivate MC4R mutations in a large, unselected European British population,
scanned by meltMADGE. Human Mutation 28(3):294e302.
[107] Saeed, S., Bonnefond, A., Manzoor, J., Shabbir, F., Ayesha, H., Philippe, J.,
et al., 2015. Genetic variants in LEP, LEPR, and MC4R explain 30% of severe
obesity in children from a consanguineous population. Obesity 23(8):1687e
1695.
[108] Lotta, L.A., Mokrosinski, J., de Oliveira, E.M., Li, C., Sharp, S.J., Luan, J.,
et al., 2019. Human gain-of-function MC4R variants show signaling bias and
protect against obesity. Cell 177(3):597e607 e9.
[109] Farooqi, I.S., Keogh, J.M., Yeo, G.S.H., Lank, E.J., Cheetham, T., O’Rahilly, S.,
2003. Clinical spectrum of obesity and mutations in the melanocortin 4 re-
ceptor gene. New England Journal of Medicine 348(12):1085e1095.
[110] Kim, K.S., Larsen, N., Short, T., Plastow, G., Rothschild, M.F., 2000. A
missense variant of the porcine melanocortin-4 receptor (MC4R) gene is
associated with fatness, growth, and feed intake traits. Mammalian Genome
11(2):131e135.
[111] Aspiras, A.C., Rohner, N., Martineau, B., Borowsky, R.L., Tabin, C.J., 2015.
Melanocortin 4 receptor mutations contribute to the adaptation of cavefish to
nutrient-poor conditions. Proceedings of the National Academy of Sciences of
the United States of America 112(31):9668e9673.
[112] Chambers, J.C., Elliott, P., Zabaneh, D., Zhang, W.H., Li, Y., Froguel, P., et al.,
2008. Common genetic variation near MC4R is associated with waist
circumference and insulin resistance. Nature Genetics 40(6):716e718.
[113] Loos, R.J., Lindgren, C.M., Li, S.X., Wheeler, E., Zhao, J.H., Prokopenko, I.,
et al., 2008. Common variants near MC4R are associated with fat mass,
weight and risk of obesity. Nature Genetics 40(6):768e775.
[114] Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G.,
Jackson, A.U., et al., 2010. Association analyses of 249,796 individuals
reveal 18 new loci associated with body mass index. Nature Genetics 42(11):
937e948.
[115] Kichaev, G., Bhatia, G., Loh, P.R., Gazal, S., Burch, K., Freund, M.K., et al.,
2019. Leveraging polygenic functional enrichment to improve GWAS power.
The American Journal of Human Genetics 104(1):65e75.
[116] Thorleifsson, G., Walters, G.B., Gudbjartsson, D.F., Steinthorsdottir, V.,
Sulem, P., Helgadottir, A., et al., 2009. Genome-wide association yields new
sequence variants at seven loci that associate with measures of obesity.
Nature Genetics 41(1):18e24.
[117] Willer, C.J., Speliotes, E.K., Loos, R.J.F., Li, S.X., Lindgren, C.M., Heid, I.M.,
et al., 2009. Six new loci associated with body mass index highlight a
neuronal influence on body weight regulation. Nature Genetics 41(1):25e34.
[118] Ayers, K.L., Glicksberg, B.S., Garfield, A.S., Longerich, S., White, J.A.,
Yang, P.W., et al., 2018. Melanocortin 4 receptor pathway dysfunction in
obesity: patient stratification aimed at MC4R agonist treatment. Journal of
Clinical Endocrinology & Metabolism 103(7):2601e2612.
[119] Schioth, H.B., Chhajlani, V., Muceniece, R., Klusa, V., Wikberg, J.E., 1996.
Major pharmacological distinction of the ACTH receptor from other melano-
cortin receptors. Life Sciences 59(10):797e801.
[120] Glembotski, C.C., 1982. Acetylation of alpha-melanotropin and beta-endor-
phin in the rat intermediate pituitary. Subcellular localization. Journal of
Biological Chemistry 257(17):10493e10500.
[121] Smith, A.I., Funder, J.W., 1988. Proopiomelanocortin processing in the pi-
tuitary, central nervous system, and peripheral tissues. Endocrine Reviews
9(1):159e179.
[122] O’Donohue, T.L., Handelmann, G.E., Chaconas, T., Miller, R.L.,
Jacobowitz, D.M., 1981. Evidence that N-acetylation regulates the behavioral
activity of alpha-MSH in the rat and human central nervous system. Peptides
2(3):333e344.
[123] Castrucci, A.M., Hadley, M.E., Sawyer, T.K., Wilkes, B.C., al-Obeidi, F.,
Staples, D.J., et al., 1989. Alpha-melanotropin: the minimal active sequence
in the lizard skin bioassay. General and Comparative Endocrinology 73(1):
157e163.14 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. T[124] Hruby, V.J., Wilkes, B.C., Hadley, M.E., Al-Obeidi, F., Sawyer, T.K.,
Staples, D.J., et al., 1987. alpha-Melanotropin: the minimal active sequence
in the frog skin bioassay. Journal of Medicinal Chemistry 30(11):2126e2130.
[125] Schwyzer, R., 1977. ACTH: a short introductory review. Annals of the New
York Academy of Sciences 297:3e26.
[126] Guo, L., Münzberg, H., Stuart, R.C., Nillni, E.A., Bjørbaek, C., 2004. N-
acetylation of hypothalamic alpha-melanocyte-stimulating hormone and
regulation by leptin. Proceedings of the National Academy of Sciences of the
United States of America 101(32):11797e11802.
[127] Oki, S., Nakao, K., Tanaka, I., Kinoshita, F., Naki, Y., Imura, H., 1982.
Characterization of gamma-melanotropin-like immunoreactivity and its
secretion in an adrenocorticotropin-producing mouse pituitary tumor cell line.
Endocrinology 111(2):418e424.
[128] van Strien, F.J., Devreese, B., Van Beeumen, J., Roubos, E.W., Jenks, B.G.,
1995. Biosynthesis and processing of the N-terminal part of proopiomela-
nocortin in Xenopus laevis: characterization of gamma-MSH peptides.
Journal of Neuroendocrinology 7(10):807e815.
[129] Grieco, P., Balse, P.M., Weinberg, D., MacNeil, T., Hruby, V.J., 2000. D-
Amino acid scan of gamma-melanocyte-stimulating hormone: importance of
Trp(8) on human MC3 receptor selectivity. Journal of Medicinal Chemistry
43(26):4998e5002.
[130] Grieco, P., Balse-Srinivasan, P., Han, G., Weinberg, D., MacNeil, T., Van der
Ploeg, L.H.T., et al., 2002. Synthesis and biological evaluation on hMC3,
hMC4 and hMC5 receptors of gamma-MSH analogs substituted with L-
alanine. The Journal of Peptide Research 59(5):203e210.
[131] Joseph, C.G., Yao, H., Scott, J.W., Sorensen, N.B., Marnane, R.N.,
Mountjoy, K.G., et al., 2010. gamma(2)-Melanocyte stimulation hormone
(gamma(2)-MSH) truncation studies results in the cautionary note that
gamma(2)-MSH is not selective for the mouse MC3R over the mouse MC5R.
Peptides 31(12):2304e2313.
[132] Kiefer, L.L., Veal, J.M., Mountjoy, K.G., Wilkison, W.O., 1998. Melanocortin
receptor binding determinants in the agouti protein. Biochemistry 37(4):991e
997.
[133] Tota, M.R., Smith, T.S., Mao, C., MacNeil, T., Mosley, R.T., Van der
Ploeg, L.H., et al., 1999. Molecular interaction of Agouti protein and Agouti-
related protein with human melanocortin receptors. Biochemistry 38(3):897e
904.
[134] Willard, D.H., Bodnar, W., Harris, C., Kiefer, L., Nichols, J.S., Blanchard, S.,
et al., 1995. Agouti structure and function: characterization of a potent alpha-
melanocyte stimulating hormone receptor antagonist. Biochemistry 34(38):
12341e12346.
[135] Creemers, J.W., Pritchard, L.E., Gyte, A., Le Rouzic, P., Meulemans, S.,
Wardlaw, S.L., et al., 2006. Agouti-related protein is posttranslationally
cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)
83-132: interaction between AGRP83-132 and melanocortin receptors
cannot be influenced by syndecan-3. Endocrinology 147(4):1621e1631.
[136] He, L., Gunn, T.M., Bouley, D.M., Lu, X.Y., Watson, S.J., Schlossman, S.F.,
et al., 2001. A biochemical function for attractin in agouti-induced pigmen-
tation and obesity. Nature Genetics 27(1):40e47.
[137] Ollmann, M.M., Lamoreux, M.L., Wilson, B.D., Barsh, G.S., 1998. Interaction
of Agouti protein with the melanocortin 1 receptor in vitro and in vivo. Genes
& Development 12(3):316e330.
[138] Fong, T.M., Mao, C., MacNeil, T., Kalyani, R., Smith, T., Weinberg, D., et al.,
1997. ART (protein product of agouti-related transcript) as an antagonist of
MC-3 and MC-4 receptors. Biochemical and Biophysical Research Commu-
nications 237(3):629e631.
[139] Yang, Y.K., Thompson, D.A., Dickinson, C.J., Wilken, J., Barsh, G.S.,
Kent, S.B., et al., 1999. Characterization of Agouti-related protein binding to
melanocortin receptors. Molecular Endocrinology 13(1):148e155.
[140] Kiefer, L.L., Ittoop, O.R., Bunce, K., Truesdale, A.T., Willard, D.H.,
Nichols, J.S., et al., 1997. Mutations in the carboxyl terminus of the agoutihis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
protein decrease agouti inhibition of ligand binding to the melanocortin re-
ceptors. Biochemistry 36(8):2084e2090.
[141] McNulty, J.C., Jackson, P.J., Thompson, D.A., Chai, B.X., Gantz, I.,
Barsh, G.S., et al., 2005. Structures of the agouti signaling protein. Journal of
Molecular Biology 346(4):1059e1070.
[142] Shutter, J.R., Graham, M., Kinsey, A.C., Scully, S., Lüthy, R., Stark, K.L.,
1997. Hypothalamic expression of ART, a novel gene related to agouti, is up-
regulated in obese and diabetic mutant mice. Genes & Development 11(5):
593e602.
[143] Haskell-Luevano, C., Monck, E.K., 2001. Agouti-related protein functions as
an inverse agonist at a constitutively active brain melanocortin-4 receptor.
Regulatory Peptides 99(1):1e7.
[144] Nijenhuis, W.A., Oosterom, J., Adan, R.A., 2001. AgRP(83-132) acts as an
inverse agonist on the human-melanocortin-4 receptor. Molecular Endocri-
nology 15(1):164e171.
[145] Agosti, F., Gonzalez, S.C., Damonte, V.M., Tolosa, M.J., Di Siervi, N.,
Schioth, H.B., et al., 2017. Melanocortin 4 receptor constitutive activity in-
hibits L-type voltage-gated calcium channels in neurons. Neuroscience 346:
102e112.
[146] Tolle, V., Low, M.J., 2008. In vivo evidence for inverse agonism of Agouti-
related peptide in the central nervous system of proopiomelanocortin-defi-
cient mice. Diabetes 57(1):86e94.
[147] Mo, X.L., Tao, Y.X., 2013. Activation of MAPK by inverse agonists in six
naturally occurring constitutively active mutant human melanocortin-4 re-
ceptors. Biochimica et Biophysica Acta 1832(12):1939e1948.
[148] Luger, T.A., Bohm, M., 2015. An alpha-MSH analog in erythropoietic pro-
toporphyria. Journal of Investigative Dermatology 135(4):929e931.
[149] Sawyer, T.K., Sanfilippo, P.J., Hruby, V.J., Engel, M.H., Heward, C.B.,
Burnett, J.B., et al., 1980. 4-Norleucine, 7-D-phenylalanine-alpha-melano-
cyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong
biological activity. Proceedings of the National Academy of Sciences of the
United States of America 77(10):5754e5758.
[150] Haskell-Luevano, C., Holder, J.R., Monck, E.K., Bauzo, R.M., 2001. Char-
acterization of melanocortin NDP-MSH agonist peptide fragments at the
mouse central and peripheral melanocortin receptors. Journal of Medicinal
Chemistry 44(13):2247e2252.
[151] Al-Obeidi, F., Castrucci, A.M., Hadley, M.E., Hruby, V.J., 1989. Potent and
prolonged acting cyclic lactam analogues of alpha-melanotropin: design
based on molecular dynamics. Journal of Medicinal Chemistry 32(12):2555e
2561.
[152] Al-Obeidi, F., Hruby, V.J., Castrucci, A.M., Hadley, M.E., 1989. Design of
potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and
10. Journal of Medicinal Chemistry 32(1):174e179.
[153] Molinoff, P.B., Shadiack, A.M., Earle, D., Diamond, L.E., Quon, C.Y., 2003. T-
141: a melanocortin agonist for the treatment of sexual dysfunction. Annals
of the New York Academy of Sciences 994:96e102.
[154] Pfaus, J.G., Shadiack, A., Van Soest, T., Tse, M., Molinoff, P., 2004. Selective
facilitation of sexual solicitation in the female rat by a melanocortin receptor
agonist. Proceedings of the National Academy of Sciences of the United
States of America 101(27):10201e10204.
[155] Kingsberg, S.A., Clayton, A.H., Portman, D., Williams, L.A., Krop, J.,
Jordan, R., et al., 2019. Bremelanotide for the treatment of hypoactive sexual
desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology
134(5):899e908.
[156] Van der Ploeg, L.H., Martin, W.J., Howard, A.D., Nargund, R.P., Austin, C.P.,
Guan, X.M., et al., 2002. A role for the melanocortin 4 receptor in sexual
function. Proceedings of the National Academy of Sciences of the United
States of America 99(17):11381e11386.
[157] Hruby, V.J., Lu, D., Sharma, S.D., Castrucci, A.L., Kesterson, R.A., al-
Obeidi, F.A., et al., 1995. Cyclic lactam alpha-melanotropin analogues of Ac-
Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist
potency and selectivity at specific melanocortin receptors. Journal of Me-
dicinal Chemistry 38(18):3454e3461. https://doi.org/10.1021/
jm00018a005.
[158] Yu, J., Gimenez, L.E., Hernandez, C.C., Wu, Y., Wein, A.H., Han, G.W., et al.,
2020. Determination of the melanocortin-4 receptor structure identifies
Ca(2+) as a cofactor for ligand binding. Science 368(6489):428e433.
[159] Hadley, M.E., Anderson, B., Heward, C.B., Sawyer, T.K., Hruby, V.J., 1981.
Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-
D-phenylalanine]-alpha-melanotropin. Science 213(4511):1025e1027.
[160] Chen, K.Y., Muniyappa, R., Abel, B.S., Mullins, K.P., Staker, P., Brychta, R.J.,
et al., 2015. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases
resting energy expenditure in obese individuals. Journal of Clinical Endocri-
nology & Metabolism 100(4):1639e1645.
[161] Clement, K., Biebermann, H., Farooqi, I.S., Van der Ploeg, L., Wolters, B.,
Poitou, C., et al., 2018. MC4R agonism promotes durable weight loss in
patients with leptin receptor deficiency. Nature Medicine 24(5):551e555.
[162] Kuhnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K.,
Martini, L.L., et al., 2016. Proopiomelanocortin deficiency treated with a
melanocortin-4 receptor agonist. New England Journal of Medicine 375(3):
240e246.
[163] Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F.,
Lingvay, I., et al., 2021. Once-weekly semaglutide in adults with overweight
or obesity. New England Journal of Medicine.
[164] Clemmensen, C., Finan, B., Fischer, K., Tom, R.Z., Legutko, B., Sehrer, L.,
et al., 2015. Dual melanocortin-4 receptor and GLP-1 receptor agonism
amplifies metabolic benefits in diet-induced obese mice. EMBO Molecular
Medicine 7(3):288e298.
[165] Lu, D., Vage, D.I., Cone, R.D., 1998. A ligand-mimetic model for constitutive
activation of the melanocortin-1 receptor. Molecular Endocrinology 12:592e
604. https://doi.org/10.1210/mend.12.4.0091.
[166] Schioth, H.B., Bouifrouri, A.A., Rudzish, R., Muceniece, R., Watanobe, H.,
Wikberg, J.E.S., et al., 2002. Pharmacological comparison of rat and human
melanocortin 3 and 4 receptors in vitro. Regulatory Peptides 106:7e12.
https://doi.org/10.1016/s0167-0115(02)00025-3.
[167] Adan, R.A., Szklarczyk, A.W., Oosterom, J., Brakkee, J.H., Nijenhuis, W.A.,
Schaaper, W.M., et al., 1999. Characterization of melanocortin receptor li-
gands on cloned brain melanocortin receptors and on grooming behavior in
the rat. European Journal of Pharmacology 378:249e258. https://doi.org/
10.1016/s0014-2999(99)00465-3.
[168] Desarnaud, F., Labbe, O., Eggerickx, D., Vassart, G., Parmentier, M., 1994.
Molecular cloning, functional expression and pharmacological characteriza-
tion of a mouse melanocortin receptor gene. Biochemical Journal 299(Pt 2):
367e373. https://doi.org/10.1042/bj2990367.
[169] Roselli-Rehfuss, L., Mountjoy, K.G., Robbins, L.S., Mortrud, M.T., Low, M.J.,
Tatro, J.B., et al., 1993. Identification of a receptor for gamma melanotropin
and other proopiomelanocortin peptides in the hypothalamus and limbic
system. Proceedings of the National Academy of Sciences of the U S A 90:
8856e8860. https://doi.org/10.1073/pnas.90.19.8856.
[170] Labbe, O., Desarnaud, F., Eggerickx, D., Vassart, G., Parmentier, M., 1994.
Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed
in peripheral tissues. Biochemistry 33:4543e4549. https://doi.org/10.1021/
bi00181a015.
[171] Gantz, I., Shimoto, Y., Konda, Y., Miwa, H., Dickinson, C.J., Yamada, T.,
1994. Molecular cloning, expression, and characterization of a fifth mela-
nocortin receptor. Biochemical and Biophysical Research Communications
200:1214e1220. https://doi.org/10.1006/bbrc.1994.1580.
[172] Schioth, H.B., Muceniece, R., Wikberg, J.E., Chhajlani, V., 1995. Charac-
terisation of melanocortin receptor subtypes by radioligand binding analysis.
European Journal of Pharmacology 288:311e317. https://doi.org/10.1016/
0922-4106(95)90043-8.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 15
Review[173] Chhajlani, V., Wikberg, J.E., 1992. Molecular cloning and expression of the
human melanocyte stimulating hormone receptor cDNA. FEBS Letters 309:
417e420. https://doi.org/10.1016/0014-5793(92)80820-7.
[174] Schioth, H.B., Müceniece, R., Mutulis, F., Prusis, P., Lindeberg, G.,
Sharma, S.D., et al., 1997. Selectivity of cyclic [D-Nal7] and [D-Phe7]
substituted MSH analogues for the melanocortin receptor subtypes. Peptides
18:1009e1013. https://doi.org/10.1016/s0196-9781(97)00079-x.
[175] Kievit, P., Halem, H., Marks, D.L., Dong, J.Z., Glavas, M.M., Sinnayah, P.,
et al., 2013. Chronic treatment with a melanocortin-4 receptor agonist
causes weight loss, reduces insulin resistance, and improves cardiovascular
function in diet-induced obese rhesus macaques. Diabetes 62:490e497.
https://doi.org/10.2337/db12-0598.
[176] Conde-Frieboes, K., Thøgersen, H., Lau, J.F., Sensfuss, U., Hansen, T.K.,
Christensen, L., et al., 2012. Identification and in vivo and in vitro charac-
terization of long acting and melanocortin 4 receptor (MC4-R) selective alpha-
melanocyte-stimulating hormone (alpha-MSH) analogues. Journal of Medic-
inal Chemistry 55:1969e1977. https://doi.org/10.1021/jm201489a.
[177] Bednarek, M.A., MacNeil, T., Tang, R., Fong, T.M., Cabello, M.A., Maroto, M.,
et al., 2007. Potent and selective peptide agonists of alpha-melanocyte
stimulating hormone (alphaMSH) action at human melanocortin receptor 5;
their synthesis and biological evaluation in vitro. Chemical Biology & Drug
Design 69:350e355. https://doi.org/10.1111/j.1747-0285.2007.00513.x.
[178] Haskell-Luevano, C., Hendrata, S., North, C., Sawyer, T.K., Hadley, M.E.,
Hruby, V.J., et al., 1997. Discovery of prototype peptidomimetic agonists at
the human melanocortin receptors MC1R and MC4R. Journal of Medicinal
Chemistry 40:2133e2139. https://doi.org/10.1021/jm960840h.
[179] Schioth, H.B., Muceniece, R., Wikberg, J.E., 1996. Characterisation of the
melanocortin 4 receptor by radioligand binding. Pharmacology & Toxicology
79:161e165. https://doi.org/10.1111/j.1600-0773.1996.tb00261.x.
[180] Chhajlani, V., Muceniece, R., Wikberg, J.E., 1993. Molecular cloning of a
novel human melanocortin receptor. Biochemical and Biophysical Research
Communications 195:866e873. https://doi.org/10.1006/bbrc.1993.2125.
[181] Yan, L.Z., Hsiung, H.M., Heiman, M.L., Gadski, R.A., Emmerson, P.J.,
Hertel, J., et al., 2007. Structure-activity relationships of beta-MSH derived
melanocortin-4 receptor peptide agonists. Current Topics in Medicinal
Chemistry 7:1052e1067. https://doi.org/10.2174/156802607780906591.
[182] Mayer, J.P., Hsiung, H.M., Flora, D.B., Edwards, Pa., Smith, D.P., Zhang, X.Y.,
et al., 2005. Discovery of a beta-MSH-derived MC-4R selective agonist.
Journal of Medicinal Chemistry 48:3095e3098. https://doi.org/10.1021/
jm0501432.
[183] Grieco, P., Balse, P.M., Weinberg, D., MacNeil, T., Hruby, V.J., 2000. D-
Amino acid scan of gamma-melanocyte-stimulating hormone: importance of
Trp(8) on human MC3 receptor selectivity. Journal of Medicinal Chemistry 43:
4998e5002. https://doi.org/10.1021/jm000211e.
[184] Durek, T., Cromm, P.M., White, A.M., Schroeder, C.I., Kaas, Q.,
Weidmann, J., et al., 2018. Development of novel melanocortin receptor
agonists based on the cyclic peptide framework of sunflower trypsin inhib-
itor-1. Journal of Medicinal Chemistry 61:3674e3684. https://doi.org/
10.1021/acs.jmedchem.8b00170.
[185] Kumar, K.G., Sutton, G.M., Dong, J.Z., Roubert, P., Plas, P., Halem, H.A.,
et al., 2009. Analysis of the therapeutic functions of novel melanocortin
receptor agonists in MC3R-and MC4R-deficient C57BL/6J mice. Peptides 30:
1892e1900.
[186] Blood, C.H., Shadiack, A.M., Bernstein, J.K., Herbert, G.H., 2001. Composi-
tions and methods for treatment of sexual dysfunction. U.S. patent.
[187] Molinoff, P.B., Shadiack, A.M., Earle, D., Diamond, L.E., Quon, C.Y., 2003.
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
Annals of the New York Academy of Sciences 994:96e102. https://doi.org/
10.1111/j.1749-6632.2003.tb03167.x.
[188] Haskell-Luevano, C., Monck, E.K., Wan, Y.P., Schentrup, A.M., 2000. The
agouti-related protein decapeptide (Yc[CRFFNAFC]Y) possesses agonist16 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. Tactivity at the murine melanocortin-1 receptor. Peptides 21:683e689.
https://doi.org/10.1016/s0196-9781(00)00194-7.
[189] Haskell-Luevano, C., Cone, R.D., Monck, E.K., Wan, Y.P., 2001. Structure
activity studies of the melanocortin-4 receptor by in vitro mutagenesis:
identification of agouti-related protein (AGRP), melanocortin agonist and
synthetic peptide antagonist interaction determinants. Biochemistry 40:
6164e6179. https://doi.org/10.1021/bi010025q.
[190] Bednarek, M.A., Macneil, T., Kalyani, R.N., Tang, R., Van der Ploeg, L.H.,
Weinberg, D.H., 1999. Analogs of MTII, lactam derivatives of alpha-mela-
notropin, modified at the N-terminus, and their selectivity at human mela-
nocortin receptors 3, 4, and 5. Biochemical and Biophysical Research
Communications 261:209e213. https://doi.org/10.1006/bbrc.1999.0981.
[191] Lensing, C.J., Freeman, K.T., Schnell, S.M., Adank, D.N., Speth, R.C., Has-
kell-Luevano, C., 2016. An in vitro and in vivo investigation of bivalent ligands
that display preferential binding and functional activity for different mela-
nocortin receptor homodimers. Journal of Medicinal Chemistry 59:3112e
3128. https://doi.org/10.1021/acs.jmedchem.5b01894.
[192] Schioth, H.B., Müceniece, R., Mutulis, F., Prusis, P., Lindeberg, G.,
Sharma, S.D., et al., 1997. Selectivity of cyclic [D-Nal(7)] and [D-Phe(7)]
substituted MSH analogues for the melanocortin receptor subtypes. Peptides
18:1009e1013.
[193] Bednarek, M.A., Macneil, T., Tang, R., Fong, T.M., Cabello, M.A., Maroto, M.,
et al., 2008. Analogs of alpha-melanocyte stimulating hormone with high
agonist potency and selectivity at human melanocortin receptor 1b: the role
of Trp(9) in molecular recognition. Biopolymers 89:401e408. https://doi.org/
10.1002/bip.20863.
[194] Bednarek, M.A., MacNeil, T., Kalyani, R.N., Tang, R., Van der Ploeg, L.H.,
Weinberg, D.H., 2001. Selective, high affinity peptide antagonists of a-
melanotropin action at human melanocortin receptor 4: their synthesis and
biological evaluation in vitro. Journal of Medicinal Chemistry 44:3665e3672.
https://doi.org/10.1021/jm010165y.
[195] Kiefer, L.L., Ittoop, O.R., Bunce, K., Truesdale, A.T., Willard, D.H.,
Nichols, J.S., et al., 1997. Mutations in the carboxyl terminus of the agouti
protein decrease agouti inhibition of ligand binding to the melanocortin re-
ceptors. Biochemistry 36:2084e2090. https://doi.org/10.1021/bi962647v.
[196] Oosterom, J., Garner, K.M., den Dekker, W.K., Nijenhuis, W.A., Gispen, W.H.,
Burbach, J.P., et al., 2001. Common requirements for melanocortin-4 re-
ceptor selectivity of structurally unrelated melanocortin agonist and endog-
enous antagonist, Agouti protein. Journal of Biological Chemistry 276:931e
936. https://doi.org/10.1074/jbc.M007261200.
[197] McNulty, J.C., Jackson, P.J., Thompson, D.A., Chai, B.X., Gantz, I.,
Barsh, G.S., et al., 2005. Structures of the agouti signaling protein. Journal of
Molecular Biology 346:1059e1070. https://doi.org/10.1016/
j.jmb.2004.12.030.
[198] Wilczynski, A., Wang, X.S., Bauzo, R.M., Xiang, Z.M., Shaw, A.M.,
Millard, W.J., et al., 2004. Structural characterization and pharmacology of a
potent (Cys101-Cys119, Cys110-Cys117) bicyclic agouti-related protein
(AGRP) melanocortin receptor antagonist. Journal of Medicinal Chemistry 47:
5662e5673. https://doi.org/10.1021/jm049620r.
[199] Yang, Y.K., Thompson, D.A., Dickinson, C.J., Wilken, J., Barsh, G.S.,
Kent, S.B., et al., 1999. Characterization of Agouti-related protein binding to
melanocortin receptors. Molecular Endocrinology 13:148e155. https://
doi.org/10.1210/mend.13.1.0223.
[200] Fong, T.M., Mao, C., MacNeil, T., Kalyani, R., Smith, T., Weinberg, D., et al.,
1997. ART (protein product of agouti-related transcript) as an antagonist of
MC-3 and MC-4 receptors. Biochemical and Biophysical Research Commu-
nications 237:629e631. https://doi.org/10.1006/bbrc.1997.7200.
[201] Tota, M.R., Smith, T.S., Mao, C., MacNeil, T., Mosley, R.T., Van der
Ploeg, L.H., et al., 1999. Molecular interaction of Agouti protein and Agouti-
related protein with human melanocortin receptors. Biochemistry 38:897e
904. https://doi.org/10.1021/bi9815602.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
[202] Proneth, B., Xiang, Z.M., Pogozheva, I.D., Litherland, S.A., Gorbatyuk, O.S.,
Shaw, A.M., et al., 2006. Molecular mechanism of the constitutive activation
of the L250Q human melanocortin-4 receptor polymorphism. Chemical
Biology & Drug Design 67:215e229. https://doi.org/10.1111/j.1747-
0285.2006.00362.x.
[203] Mountjoy, K.G., 1994. The human melanocyte stimulating hormone receptor
has evolved to become "super-sensitive" to melanocortin peptides. Molecular
and Cellular Endocrinology 102:R7eR11. https://doi.org/10.1016/0303-
7207(94)90113-9.
[204] Wilczynski, A., Wang, X.S., Joseph, C.G., Xiang, Z.M., Bauzo, R.M.,
Scott, J.W., et al., 2004. Identification of putative agouti-related protein(87-
132)-melanocortin-4 receptor interactions by homology molecular modeling
and validation using chimeric peptide ligands. Journal of Medicinal Chemistry
47:2194e2207. https://doi.org/10.1021/jm0303608.
[205] Joseph, C.G., Yao, H., Scott, J.W., Sorensen, N.B., Marnane, R.N.,
Mountjoy, K.G., et al., 2010. gamma(2)-Melanocyte stimulation hormone
(gamma(2)-MSH) truncation studies results in the cautionary note that
gamma(2)-MSH is not selective for the mouse MC3R over the mouse MC5R.
Peptides 31:2304e2313. https://doi.org/10.1016/j.peptides.2010.08.025.
[206] Alvaro, J.D., Tatro, J.B., Quillan, J.M., Fogliano, M., Eisenhard, M.,
Lerner, M.R., et al., 1996. Morphine down-regulates melanocortin-4 receptor
expression in brain regions that mediate opiate addiction. Molecular Phar-
macology 50:583e591.
[207] Griffon, N., Mignon, V., Facchinetti, P., Diaz, J., Schwartz, J.C., Sokoloff, P.,
1994. Molecular cloning and characterization of the rat fifth melanocortin
receptor. Biochemical and Biophysical Research Communications 200:
1007e1014. https://doi.org/10.1006/bbrc.1994.1550.
[208] Palmer, D., Gonçalves, J.P.L., Hansen, L.V., Wu, B.Q., Hald, H.,
Schoffelen, S., et al., 2017. Click-chemistry-mediated synthesis of selective
melanocortin receptor 4 agonists. Journal of Medicinal Chemistry 60:8716e
8730. https://doi.org/10.1021/acs.jmedchem.7b00353.
[209] Xiang, Z., Proneth, B., Dirain, M.L., Litherland, S.A., Haskell-Luevano, C.,
2010. Pharmacological characterization of 30 human melanocortin-4 re-
ceptor polymorphisms with the endogenous proopiomelanocortin-derived
agonists, synthetic agonists, and the endogenous agouti-related protein
antagonist. Biochemistry 49:4583e4600. https://doi.org/10.1021/
bi100068u.
[210] Mountjoy, K.G., Mortrud, M.T., Low, M.J., Simerly, R.B., Cone, R.D., 1994.
Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and
autonomic control circuits in the brain. Molecular Endocrinology 8:1298e
1308. https://doi.org/10.1210/mend.8.10.7854347.
[211] Fathi, Z., Iben, L.G., Parker, E.M., 1995. Cloning, expression, and tissue
distribution of a fifth melanocortin receptor subtype. Neurochemical Research
20:107e113. https://doi.org/10.1007/BF00995160.
[212] Cai, M., Stankova, M., Muthu, D., Mayorov, A., Yang, Z.H., Trivedi, D., et al.,
2013. An unusual conformation of gamma-melanocyte-stimulating hormone
analogues leads to a selective human melanocortin 1 receptor antagonist for
targeting melanoma cells. Biochemistry 52:752e764. https://doi.org/
10.1021/bi300723f.
[213] Haskell-Luevano, C., Lim, S., Yuan, W., Cone, R.D., Hruby, V.J., 2000.
Structure activity studies of the melanocortin antagonist SHU9119 modified
at the 6, 7, 8, and 9 positions. Peptides 21:49e57. https://doi.org/10.1016/
s0196-9781(99)00167-9.
[214] Tala, S.R., Schnell, S.M., Haskell-Luevano, C., 2015. Microwave-assisted
solid-phase synthesis of side-chain to side-chain lactam-bridge cyclic pep-
tides. Bioorganic & Medicinal Chemistry Letters 25:5708e5711. https://
doi.org/10.1016/j.bmcl.2015.10.095.
[215] Qu, H., Cai, M.Y., Mayorov, A.V., Grieco, P., Zingsheim, M., Trivedi, D., et al.,
2009. Substitution of arginine with proline and proline derivatives in mela-
nocyte-stimulating hormones leads to selectivity for human melanocortin 4MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comreceptor. Journal of Medicinal Chemistry 52:3627e3635. https://doi.org/
10.1021/jm801300c.
[216] Grieco, P., Han, G., Weinberg, D., Van der Ploeg, L.H., Hruby, V.J., 2002.
Design and synthesis of highly potent and selective melanotropin analogues
of SHU9119 modified at position 6. Biochemical and Biophysical Research
Communications 292:1075e1080. https://doi.org/10.1006/bbrc.2002.6739.
[217] Mowlazadeh Haghighi, S., Zhou, Y., Dai, J.X., Sawyer, J.R., Hruby, V.J.,
Cai, M.Y., 2018. Replacement of Arg with Nle and modified D-Phe in the core
sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity
and pigmentation. The European Journal Medicinal Chemistry 151:815e823.
https://doi.org/10.1016/j.ejmech.2018.04.021.
[218] Haskell-Luevano, C., Holder, J.R., Monck, E.K., Bauzo, R.M., 2001. Char-
acterization of melanocortin NDP-MSH agonist peptide fragments at the
mouse central and peripheral melanocortin receptors. Journal of Medicinal
Chemistry 44:2247e2252.
[219] Lensing, C.J., Freeman, K.T., Schnell, S.M., Adank, D.N., Speth, R.C., Has-
kell-Luevano, C., 2016. An in vitro and in vivo investigation of bivalent ligands
that display preferential binding and functional activity for different mela-
nocortin receptor homodimers. Journal of Medicinal Chemistry 59:3112e
3128.
[220] Ericson, M.D., Freeman, K.T., Schnell, S.M., Fleming, K.A., Haskell-
Luevano, C., 2017. Structure-Activity relationship studies on a macrocyclic
Agouti-related protein (AGRP) scaffold reveal Agouti signaling protein (ASP)
residue substitutions maintain melanocortin-4 receptor antagonist potency
and result in inverse agonist pharmacology at the melanocortin-5 receptor.
Journal of Medicinal Chemistry 60:8103e8114. https://doi.org/10.1021/
acs.jmedchem.7b00856.
[221] Tala, S.R., Schnell, S.M., Haskell-Luevano, C., 2015. Microwave-assisted
solid-phase synthesis of side-chain to side-chain lactam-bridge cyclic pep-
tides. Bioorganic & Medicinal Chemistry Letters 25:5708e5711.
[222] Yang, Y.K., Ollmann, M.M., Wilson, B.D., Dickinson, C., Yamada, T.,
Barsh, G.S., et al., 1997. Effects of recombinant agouti-signaling protein on
melanocortin action. Molecular Endocrinology 11:274e280. https://doi.org/
10.1210/mend.11.3.9898.
[223] Wessells, H., Gralnek, D., Dorr, R., Hruby, V.J., Hadley, M.E., Levine, N.,
2000. Effect of an alpha-melanocyte stimulating hormone analog on penile
erection and sexual desire in men with organic erectile dysfunction. Urology
56:641e646. https://doi.org/10.1016/s0090-4295(00)00680-4.
[224] Clayton, A.H., Althof, S.E., Kingsberg, S., DeRogatis, L.R., Kroll, R.,
Goldstein, I., et al., 2016. Bremelanotide for female sexual dysfunctions in
premenopausal women: a randomized, placebo-controlled dose-finding trial.
Women’s Health 12:325e337. https://doi.org/10.2217/whe-2016-0018.
[225] Lansdell, M.I., Hepworth, D., Calabrese, A., Brown, A.D., Blagg, J.,
Burring, D.J., et al., 2010. Discovery of a selective small-molecule mela-
nocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction
in humans. Journal of Medicinal Chemistry 53:3183e3197. https://doi.org/
10.1021/jm9017866.
[226] Krishna, R., Gumbiner, B., Stevens, C., Musser, B., Mallick, M.,
Suryawanshi, S., et al., 2009. Potent and selective agonism of the mela-
nocortin receptor 4 with MK-0493 does not induce weight loss in obese
human subjects: energy intake predicts lack of weight loss efficacy. Clinical
Pharmacology & Therapeutics 86:659e666. https://doi.org/10.1038/
clpt.2009.167.
[227] Greenfield, J.R., Miller, J.W., Keogh, J.M., Henning, E., Satterwhite, J.H.,
Cameron, G.S., et al., 2009. Modulation of blood pressure by central mela-
nocortinergic pathways. New England Journal of Medicine 360:44e52.
https://doi.org/10.1056/NEJMoa0803085.
[228] Royalty, J.E., Konradsen, G., Eskerod, O., Wulff, B.S., Hansen, B.S., 2014.
Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics
of single and multiple doses of a long-acting alpha-MSH analog in healthyccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 17
Reviewoverweight and obese subjects. The Journal of Clinical Pharmacology 54:
394e404. https://doi.org/10.1002/jcph.211.
[229] Eneli, I., Xu, J.Y., Webster, M., McCagg, A., Van Der Ploeg, L., Garfield, A.S.,
et al., 2019. Tracing the effect of the melanocortin-4 receptor pathway in
obesity: study design and methodology of the TEMPO registry. The Appli-
cation of Clinical Genetics 12:87e93. https://doi.org/10.2147/
TACG.S199092.
[230] Kuhnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K.,
Martini, L.L., et al., 2016. Proopiomelanocortin deficiency treated with a
melanocortin-4 receptor agonist. New England Journal of Medicine 375:
240e246. https://doi.org/10.1056/NEJMoa1512693.
[231] FDA approves new treatment for hypoactive sexual desire disorder in pre-
menopausal women, June 21, 2019. Press Release, Source. https://www.18 MOLECULAR METABOLISM 48 (2021) 101206  2021 The Authors. Published by Elsevier GmbH. Tfda.gov/news-events/press-announcements/fda-approves-new-treatment-
hypoactive-sexual-desire-disorder-premenopausal-women.
[232] AstraZeneca PLC-palatin technologies halts phase I obesity trial, June 20,
2012. Press release: Accessed from: https://wwwbiospacecom/article/
releases/astrazeneca-plc-palatin-technologies-halts-phase-i-obesity-trial-/.
[233] Clement, K., Biebermann, H., Farooqi, I.S., Van der Ploeg, L., Wolters, B.,
Poitou, C., et al., 2018. MC4R agonism promotes durable weight loss in
patients with leptin receptor deficiency. Nature Medicine 24(5):551e555.
[234] Haws, R., Brady, S., Davis, E., Fletty, K., Yuan, G.J., Gordon, G., et al., 2020.
Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in
Bardet-Biedl syndrome. Diabetes, Obesity and Metabolism 22(11):2133e
2140. https://doi.org/10.1111/dom.14133. Epub 2020 Jul 22. PMID:
32627316; PMCID: PMC7689750.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
